[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4633
1. Abe K, Thung SN, Wu HC, Tran TT, Le Hoang P, Truong KD, Inui A, Jang JJ, Su IJ: Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. Cancer Sci; 2009 Dec;100(12):2249-54
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although many studies on the risk factors and their carcinogenesis in adult hepatocellular carcinoma (HCC) have been reported, they remain poorly understood in childhood HCC.
  • The HBV pre-S2 deletion mutant at nt 4-57 which has a CD8 T-cell epitope could be responsible for the emergence and aggressive outcome of childhood HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Gene Deletion. Hepatitis B Surface Antigens / genetics. Hepatitis B virus / genetics. Liver Neoplasms / etiology. Protein Precursors / genetics

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19719772.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens; 0 / Protein Precursors; 0 / presurface protein 2, hepatitis B surface antigen
  •  go-up   go-down


2. Beer S, Bellovin DI, Lee JS, Komatsubara K, Wang LS, Koh H, Börner K, Storm TA, Davis CR, Kay MA, Felsher DW, Grimm D: Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. Mol Ther; 2010 Jan;18(1):161-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice.
  • As expected, the shRNAs silenced hepatic p53 and accelerated liver tumorigenesis when MYC was concurrently expressed.
  • In MYC-expressing transgenic mice, the marginal shRNA-induced liver injury sufficed to further stimulate hepatocellular division that was in turn associated with markedly increased expression of the mitotic cyclin B1.
  • Hence, even at low doses, shRNAs can cause low-level hepatoxicity that can facilitate the ability of the MYC oncogene to induce liver tumorigenesis.
  • [MeSH-major] Carcinoma, Hepatocellular / chemically induced. Genes, myc / physiology. Liver Neoplasms, Experimental / chemically induced. RNA, Small Interfering / adverse effects

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2001 Mar;33(3):738-50 [11230756.001]
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:653-99 [11031250.001]
  • [Cites] Gene Ther. 2001 Aug;8(16):1248-54 [11509958.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6487-93 [11522645.001]
  • [Cites] Adv Cancer Res. 2002;84:81-154 [11885563.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6274-9 [11983916.001]
  • [Cites] Semin Liver Dis. 2002;22(2):137-44 [12016545.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):339-46 [12149612.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] Nature. 2003 Jan 16;421(6920):290-4 [12529648.001]
  • [Cites] Curr Gene Ther. 2003 Aug;3(4):281-304 [12871018.001]
  • [Cites] Front Biosci. 1998 Feb 15;3:d250-68 [9468463.001]
  • [Cites] Nature. 2004 Oct 28;431(7012):1112-7 [15475948.001]
  • [Cites] Pharmacol Ther. 1989;43(1):139-54 [2675128.001]
  • [Cites] Cell. 1989 Dec 22;59(6):1145-56 [2598264.001]
  • [Cites] Cancer Res. 1990 Jun 1;50(11):3400-7 [1692259.001]
  • [Cites] Cell. 1993 Nov 5;75(3):451-62 [8106172.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1237-45 [7977654.001]
  • [Cites] Hepatology. 1995 Oct;22(4 Pt 1):1316-25 [7557887.001]
  • [Cites] J Virol. 1996 Jul;70(7):4646-54 [8676491.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8 [8855286.001]
  • [Cites] J Biol Chem. 1998 Jun 19;273(25):15639-45 [9624157.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):1-11 [9858526.001]
  • [Cites] Carcinogenesis. 1999 Jan;20(1):41-9 [9934848.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3940-4 [10097142.001]
  • [Cites] Oncogene. 1999 May 13;18(19):2934-41 [10378690.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Semin Liver Dis. 1999;19(3):243-52 [10518304.001]
  • [Cites] PLoS Biol. 2004 Nov;2(11):e332 [15455033.001]
  • [Cites] J Virol. 2005 Jan;79(1):214-24 [15596817.001]
  • [Cites] Methods Enzymol. 2005;392:381-405 [15644194.001]
  • [Cites] Toxicol Pathol. 2005;33(1):181-4 [15805070.001]
  • [Cites] Cancer Biol Ther. 2004 Oct;3(10):942-4 [15611633.001]
  • [Cites] Gene Ther. 2006 Mar;13(6):563-75 [16453009.001]
  • [Cites] Nature. 2006 May 25;441(7092):537-41 [16724069.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7390-4 [16885332.001]
  • [Cites] Nat Methods. 2006 Sep;3(9):689-95 [16929313.001]
  • [Cites] Genome Biol. 2006;7(8):231 [16942630.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):14917-22 [17848523.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):43-50 [18066065.001]
  • [Cites] J Virol. 2008 Jun;82(12):5887-911 [18400866.001]
  • [Cites] J Biol Chem. 2008 Jul 11;283(28):19184-91 [18456653.001]
  • [Cites] J Biol Chem. 2008 Aug 8;283(32):22186-92 [18524776.001]
  • [Cites] Mol Ther. 2008 Sep;16(9):1630-6 [18665161.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Oct;9(10):810-5 [18698328.001]
  • [Cites] Cell. 2009 Jun 12;137(6):1005-17 [19524505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2229-34 [10688915.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2000;40:42-65 [10836127.001]
  • [Cites] Mol Carcinog. 2000 Jul;28(3):168-73 [10942533.001]
  • [Cites] J Virol. 2001 Aug;75(15):6969-76 [11435577.001]
  • (PMID = 19844192.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA03423; United States / NCI NIH HHS / CA / R01-CA89305; United States / NIDDK NIH HHS / DK / DK078424; United States / NCI NIH HHS / CA / F32-CA132312; United States / NCI NIH HHS / CA / R01 CA089305; United States / NCI NIH HHS / CA / F32 CA132312; United States / NIDDK NIH HHS / DK / R01 DK078424; United States / NCI NIH HHS / CA / P50-CA114747; United States / NCI NIH HHS / CA / R01 CA105102; United States / NCI NIH HHS / CA / R01-CA105102; United States / NCI NIH HHS / CA / P50 CA114747
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ PMC2839214
  •  go-up   go-down


3. Moya Herráiz A, Torres-Quevedo R, Mir Pallardó J: [Liver transplant in patients with hepatocellular carcinoma]. Cir Esp; 2008 Sep;84(3):117-24
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver transplant in patients with hepatocellular carcinoma].
  • [Transliterated title] Trasplante hepático en pacientes con carcinoma hepatocelular.
  • Liver transplant in patients with cirrhosis and hepatocellular carcinoma is indicated in the early stages of the disease, which can be achieved with early detection programs using liver ultrasound.
  • Surgery is the treatment of choice in these patients, and liver transplant, from a theoretical point of view, is the best.
  • The best liver transplant results are obtained in these patients using the Milan criteria, with survivals that exceed 70% and recurrence indices of 15%, at 5 years.
  • Nowadays we have the possibility of using neo-adjuvant treatments to transplant, such as arterial chemoembolisation, percutaneous ablation techniques, and even liver resection as a bridging technique.
  • The survival of patients transplanted due to liver cancer is similar to that obtained for other non-tumour diseases.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / mortality. Liver Neoplasms / surgery. Liver Transplantation / statistics & numerical data
  • [MeSH-minor] Adult. Humans. Middle Aged. Spain / epidemiology. Survival Rate

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783669.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Woodard LE, Keravala A, Jung WE, Wapinski OL, Yang Q, Felsher DW, Calos MP: Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma. PLoS One; 2010 Jun 29;5(6):e11367
eagle-i research resources. PMID 20614008 (Special Collections) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma.
  • BACKGROUND: Hydrodynamic injection is an effective method for DNA delivery in mouse liver and is being translated to larger animals for possible clinical use.
  • METHODOLOGY/PRINCIPAL FINDINGS: To study whether hydrodynamic delivery alone, or in conjunction with delivery of phiC31 integrase for long-term transgene expression, could facilitate tumor formation, we used a transgenic mouse model in which sustained induction of the human C-MYC oncogene in the liver was followed by hydrodynamic injection.
  • In contrast, when active or inactive phiC31 integrase and donor plasmid were supplied to the mouse liver, the median tumor latency was 153 days, similar to mice receiving no injection.
  • However, in groups lacking phiC31 integrase, hydrodynamic injection appeared to contribute to C-MYC-induced hepatocellular carcinoma in adult mice.

  • COS Scholar Universe. author profiles.
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Ther. 2005 Oct;12(4):763-71 [16084128.001]
  • [Cites] Methods Mol Biol. 2005;308:99-106 [16082029.001]
  • [Cites] J Mol Biol. 2006 Mar 17;357(1):28-48 [16414067.001]
  • [Cites] Nat Biotechnol. 2006 Jun;24(6):687-96 [16732270.001]
  • [Cites] Gene Ther. 2006 Aug;13(15):1188-90 [16672982.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11730-5 [16864781.001]
  • [Cites] Hum Gene Ther. 2006 Aug;17(8):871-6 [16942446.001]
  • [Cites] Nucleic Acids Res. 2006;34(21):6298-304 [17098929.001]
  • [Cites] Curr Gene Ther. 2006 Dec;6(6):633-45 [17168696.001]
  • [Cites] Hum Gene Ther. 2006 Nov;17(11):1077-94 [17069535.001]
  • [Cites] Science. 2007 Jul 27;317(5837):477 [17656716.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14771-6 [17785413.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1866-75 [17991809.001]
  • [Cites] Gene Ther. 2008 Mar;15(6):452-62 [18004400.001]
  • [Cites] Cancer Gene Ther. 2008 Apr;15(4):225-30 [18259214.001]
  • [Cites] Mol Ther. 2008 Jun;16(6):1098-104 [18398428.001]
  • [Cites] PLoS One. 2008;3(6):e2493 [18560566.001]
  • [Cites] Lymphat Res Biol. 2008;6(3-4):149-54 [19093787.001]
  • [Cites] Mol Ther. 2009 Jan;17(1):112-20 [19002165.001]
  • [Cites] Mol Ther. 2009 Mar;17(3):491-9 [19156134.001]
  • [Cites] BMC Biotechnol. 2009;9:31 [19341467.001]
  • [Cites] Mol Ther. 2010 Jan;18(1):161-70 [19844192.001]
  • [Cites] Gene Ther. 2010 Feb;17(2):217-26 [19847205.001]
  • [Cites] Mol Ther. 2010 Jul;18(7):1346-56 [20424600.001]
  • [Cites] Mol Biol Rep. 2010 Jul;37(6):2809-16 [19757154.001]
  • [Cites] Hum Gene Ther. 2010 Oct;21(10):1287-97 [20497035.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(12):3926-34 [11359900.001]
  • [Cites] Nat Biotechnol. 2002 Nov;20(11):1124-8 [12379870.001]
  • [Cites] Curr Biol. 2004 Jun 8;14(11):R425-7 [15182690.001]
  • [Cites] Nature. 2004 Oct 28;431(7012):1112-7 [15475948.001]
  • [Cites] Mod Pathol. 1996 Feb;9(2):95-8 [8657726.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8 [8855286.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3940-4 [10097142.001]
  • [Cites] Hum Gene Ther. 1999 Jul 1;10(10):1735-7 [10428218.001]
  • [Cites] Gene Ther. 1999 Jul;6(7):1258-66 [10455434.001]
  • [Cites] Oncology. 1999;57(2):157-63 [10461064.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] PLoS Biol. 2004 Nov;2(11):e332 [15455033.001]
  • [Cites] Mol Ther. 2005 Mar;11(3):399-408 [15727936.001]
  • [Cites] Mol Ther. 2005 May;11(5):695-706 [15851008.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):419-24 [16387861.001]
  • (PMID = 20614008.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009302; United States / NCI NIH HHS / CA / CA89305-01A1; United States / NCI NIH HHS / CA / P01 CA034233; United States / NCI NIH HHS / CA / CA034233; United States / NHLBI NIH HHS / HL / R01 HL068112; United States / NCI NIH HHS / CA / R01 CA089305; United States / NHLBI NIH HHS / HL / HL068112; United States / NHLBI NIH HHS / HL / R56 HL068112; United States / NCI NIH HHS / CA / CA09302
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 2.7.7.- / Integrases
  • [Other-IDs] NLM/ PMC2894073
  •  go-up   go-down


5. Hodges KB, Cummings OW, Saxena R, Wang M, Zhang S, Lopez-Beltran A, Montironi R, Nour H, Cheng L: Clonal origin of multifocal hepatocellular carcinoma. Cancer; 2010 Sep 1;116(17):4078-85
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal origin of multifocal hepatocellular carcinoma.
  • BACKGROUND: Hepatocellular carcinoma is the most common primary tumor of the liver.
  • The clonal origin of multiple hepatocellular carcinomas is uncertain.
  • METHODS: The authors analyzed 31 tumors from 12 different patients (11 women, 1 man), who had multiple hepatocellular carcinomas involving 1 or both lobes.
  • Concordant LOH patterns between separate hepatocellular carcinomas in individual patients were seen in 8 (80%) of 10 cases, whereas discordant patterns were seen in 2 (20%) of 10 cases.
  • CONCLUSIONS: The data suggested that the significant proportion of patients with multifocal hepatocellular carcinomas have tumors of common clonal origin.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Genes, p53. Liver Neoplasms / genetics. Loss of Heterozygosity. X Chromosome Inactivation
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Mutation

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Cancer 2010. (c) 2010 American Cancer Society.
  • (PMID = 20564142.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Wang CX, Song W, Li ZJ, Song B, Wu DH, Sun AM, Chen LH: [MicroRNA profiling in patients with hepatocellular carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 May;30(5):976-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MicroRNA profiling in patients with hepatocellular carcinoma].
  • OBJECTIVE: To investigate the differential expression of microRNAs between human hepatocellular carcinoma (HCC) and liver cirrhosis (LC).
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Gene Expression Profiling. Liver Cirrhosis / genetics. Liver Neoplasms / genetics. MicroRNAs / genetics
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20501372.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


7. Kinoshita Y, Tajiri T, Souzaki R, Tatsuta K, Higashi M, Izaki T, Takahashi Y, Taguchi T: Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study. J Pediatr Hematol Oncol; 2008 Jun;30(6):447-50
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study.
  • BACKGROUND AND PURPOSE: The serum alpha-fetoprotein (AFP) level has been used as a tumor marker for hepatoblastoma, and malignant germ cell tumors in pediatric patients.
  • The AFP has 3 isoforms (L1, L2, L3), and the usefulness of the L3 fraction as a diagnostic marker for the adult hepatocellular carcinoma is well known.
  • MATERIALS AND METHODS: From 2003 to 2006, two cases of hepatoblastoma, and 5 cases of germ cell tumor, all of which were neoinfantile, were treated in our department.
  • DISCUSSION: Our results indicated that the level of the L3 fraction accurately confirmed the existence, or the malignant potential of hepatic tumor or germ cell tumor.
  • [MeSH-major] Biomarkers, Tumor / blood. Hepatoblastoma / blood. Liver Neoplasms / blood. Neoplasms, Germ Cell and Embryonal / blood. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525461.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins; 0 / Protein Isoforms; 0 / alpha-Fetoproteins
  •  go-up   go-down


8. Tsai S, Gurakar A, Anders R, Lam-Himlin D, Boitnott J, Pawlik TM: Management of large hepatocellular carcinoma in adult patients with Alagille syndrome: a case report and review of literature. Dig Dis Sci; 2010 Nov;55(11):3052-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of large hepatocellular carcinoma in adult patients with Alagille syndrome: a case report and review of literature.
  • BACKGROUND: Alagille syndrome is a multi-system developmental disorder associated with paucity of interlobular bile ducts and cholestasis, rarely associated with hepatocellular carcinoma.
  • As such, we herein review the modern management of a large hepatocellular carcinoma in an adult patient with Alagille syndrome and review the literature of adult Alagille patients with hepatocellular carcinoma.
  • CASE PRESENTATION: A 29-year-old woman with a history of Alagille syndrome was referred with biopsy-proven 12 × 8 cm hepatocellular carcinoma replacing her right liver.
  • Biopsy of the contralateral liver demonstrated findings consistent with Alagille syndrome, but no underlying cirrhosis.
  • CT volumetrics demonstrated a future liver remnant of 40%.
  • [MeSH-major] Alagille Syndrome / epidemiology. Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / epidemiology. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Comorbidity. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed


9. Salguero FJ, Richard A, Gough J, Long A, Weyer U, Cooley WA, Chambers MA, Lesellier S: Pelioid hepatocellular carcinoma in an adult Eurasian badger (Meles meles). J Comp Pathol; 2010 Feb-Apr;142(2-3):208-12
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelioid hepatocellular carcinoma in an adult Eurasian badger (Meles meles).
  • A mass was identified within the left lateral lobe of the liver of a 10-year-old Eurasian badger (Meles meles).
  • The histological appearance was consistent with hepatocellular carcinoma (HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / veterinary. Liver / pathology. Liver Neoplasms / veterinary. Mustelidae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2009. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19683720.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Wilson FD, Fitzgerald SD, Kiupel M, Walker RL, Williams CB, Todd DJ: Occurrence of hepatocellular carcinoma in an adult male Nile lechwe (Kobus megaceros). J Zoo Wildl Med; 2007 Jun;38(2):329-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of hepatocellular carcinoma in an adult male Nile lechwe (Kobus megaceros).
  • The liver was grossly enlarged and contained a smooth-surfaced nodular mass that occupied the majority of the right lobe of the liver.
  • The mass had a liver-like appearance exhibiting a tan-red coloration but having a soft consistency.
  • To our knowledge, this is the first report in the scientific literature of a naturally occurring case of hepatocellular carcinoma in a Nile lechwe or in any antelope species.
  • [MeSH-major] Antelopes. Carcinoma, Hepatocellular / veterinary. Liver Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679519.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Masuda T, Beppu T, Horino K, Komori H, Hayashi H, Okabe H, Ootao R, Horlad H, Baba Y, Miyase S, Takamori H, Baba H: Occurrence of hepatocellular carcinoma after hepatoblastoma resection in an adult with hepatitis C virus. Hepatol Res; 2009 May;39(5):525-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of hepatocellular carcinoma after hepatoblastoma resection in an adult with hepatitis C virus.
  • In patients with no indication for a hepatic resection, the prognosis of adult hepatoblastoma is quite poor.
  • A 54-year-old man with hepatitis C virus-associated liver cirrhosis was initially treated with a hepatic resection for a hepatic tumor, 3 cm in diameter.
  • The tumor consisted of osteoid-like and cartilaginous foci, myxomatous stroma, and poorly differentiated hepatocellular carcinomatous cells and was diagnosed as a mixed epithelial and mesenchymal hepatoblastoma.
  • Two years after the first operation, multicentric hepatocellular carcinomas developed in the remnant liver and were successfully treated with a secondary hepatic resection combined with radio-frequency ablation.
  • To the best of our knowledge, the primary hepatoblastoma was the smallest such tumor reported and this is the first report of a metachronous hepatoblastoma and hepatocellular carcinoma in an adult hepatitis patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19207587.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


12. Varela M, Reig M, de la Mata M, Matilla A, Bustamante J, Pascual S, Turnes J, Aracil C, Del Val A, Pascasio JM, Rodríguez M, Bruix J: [Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers]. Med Clin (Barc); 2010 May 8;134(13):569-76
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers].
  • [Transliterated title] Tratamiento del carcinoma hepatocelular en España. Análisis de 705 casos en 62 centros.
  • BACKGROUND AND OBJECTIVE: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis and its current situation in Spain is not well known.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Embolization, Therapeutic / statistics & numerical data. Hepatectomy / statistics & numerical data. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Comorbidity. Early Diagnosis. Female. Hemochromatosis / epidemiology. Hepatitis, Viral, Human / epidemiology. Humans. Liver Cirrhosis / epidemiology. Male. Mass Screening. Niacinamide / analogs & derivatives. Obesity / epidemiology. Phenylurea Compounds. Prospective Studies. Pyridines / therapeutic use. Registries. Retrospective Studies. Spain / epidemiology. Treatment Outcome. Young Adult. Yttrium Radioisotopes / therapeutic use

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20036398.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Yttrium Radioisotopes; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


13. Cosme A, Montalvo I, Sánchez J, Ojeda E, Torrado J, Zapata E, Bujanda L, Gutiérrez A, Arenas I: [Type III glycogen storage disease associated with hepatocellular carcinoma]. Gastroenterol Hepatol; 2005 Dec;28(10):622-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Type III glycogen storage disease associated with hepatocellular carcinoma].
  • [Transliterated title] Glucogenosis tipo III asociada a carcinoma hepatocelular.
  • It is characterized by accumulation of abnormal glycogen in the liver and, in 80% of patients, in muscle.
  • The liver can also show fibrosis and sometimes cirrhosis.
  • We present the case of a 31-year-old woman, diagnosed in childhood with type III glycogen storage disease, who 30 years after onset developed a hepatocellular carcinoma with portal thrombosis in the context of advanced cirrhosis.
  • This is the first case to be reported in the Spanish literature of type III glycogen storage disease associated with hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Liver Neoplasms / etiology
  • [MeSH-minor] Adult. Ascites / etiology. Biomarkers, Tumor / blood. Disease Progression. Fatal Outcome. Female. Glycogen Storage Disease Type III / complications. Humans. Liver Cirrhosis / etiology. Neoplasm Proteins / blood. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Glycogen Storage Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16373012.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins
  •  go-up   go-down


14. Chekmareva IA, Vtiurin BV, Dubova EA, Shchegolev AI: [Ultrastructural characteristics of hepatocellular carcinoma]. Arkh Patol; 2010 May-Jun;72(3):7-12
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ultrastructural characteristics of hepatocellular carcinoma].
  • The histological study diagnosed low-, moderate, and high-grade hepatocellular carcinoma in 5, 12, 5 patients, respectively.
  • The high-grade type was characterized by the signs of significant cell structural and functional rearrangement; changes in the number, sizes, and shape of intracellular masses (a nucleus, mitochondria, endoplasmic network, lysosomes).
  • [MeSH-major] Carcinoma, Hepatocellular / ultrastructure. Liver Neoplasms / ultrastructure
  • [MeSH-minor] Adolescent. Female. Humans. Liver / ultrastructure. Male. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20734825.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


15. Pila Pérez R, Pila Peláez R, Rosales Torres P, Holguín Prieto VA, Alzate Giraldo LF: [Sarcoidosis and fibrolamellar carcinoma of the liver]. An Med Interna; 2007 Sep;24(9):431-4
MedlinePlus Health Information. consumer health - Sarcoidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sarcoidosis and fibrolamellar carcinoma of the liver].
  • [Transliterated title] Sarcoidosis y carcinoma fibrolamelar del hígado.
  • The case of 20-years female patient with the diagnosis of sarcoidosis associated to fibrolamellar carcinoma of the liver is presented.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Diseases / complications. Liver Neoplasms / pathology. Sarcoidosis / complications
  • [MeSH-minor] Adult. Female. Humans


16. Korangy F, Höchst B, Manns MP, Greten TF: Immunotherapy of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol; 2010 Jun;4(3):345-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy of hepatocellular carcinoma.
  • Hepatocellular carcinoma (HCC) represents the third most common cause of cancer-related death worldwide and efficient treatment options are urgently needed.
  • Different immunotherapeutic approaches including peptide- and dendritic cell-based therapies have demonstrated promising results in patients with HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Immunotherapy / methods. Liver Neoplasms / therapy. Tumor Escape / immunology
  • [MeSH-minor] Adult. Antigens, Neoplasm / immunology. Dendritic Cells / immunology. Humans. Indoleamine-Pyrrole 2,3,-Dioxygenase / immunology. Killer Cells, Natural / immunology. T-Lymphocytes, Regulatory / immunology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20528121.001).
  • [ISSN] 1747-4132
  • [Journal-full-title] Expert review of gastroenterology & hepatology
  • [ISO-abbreviation] Expert Rev Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Indoleamine-Pyrrole 2,3,-Dioxygenase
  • [Number-of-references] 111
  •  go-up   go-down


17. Chung YE, Park MS, Park YN, Lee HJ, Seok JY, Yu JS, Kim MJ: Hepatocellular carcinoma variants: radiologic-pathologic correlation. AJR Am J Roentgenol; 2009 Jul;193(1):W7-13
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma variants: radiologic-pathologic correlation.
  • OBJECTIVE: The purpose of this article is to show the imaging findings of variant types of hepatocellular carcinoma (HCC) with pathologic correlations.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Liver Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542386.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


18. Zadrozny LM, Williams CV, Remick AK, Cullen JM: Spontaneous hepatocellular carcinoma in captive prosimians. Vet Pathol; 2010 Mar;47(2):306-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous hepatocellular carcinoma in captive prosimians.
  • Spontaneous hepatocellular carcinoma has been reported as a relatively common neoplasm in prosimians; however, the cause is unknown.
  • To investigate possible pathogenic mechanisms, the authors performed a review of all adult animals from a captive prosimian population that had postmortem examinations over the past 10 years.
  • They performed a detailed histologic evaluation of all suspected proliferative liver lesions and diagnosed hepatocellular carcinoma in 14 of 145 lemurs (9.7%).
  • Thirty-one animals-9 with hepatocellular carcinomas and 22 age-matched controls without hepatic neoplasia-were tested to evaluate the relationship between hepatic iron stores (as well as other trace metals) and the presence of hepatocellular carcinoma.
  • There was no difference between the hepatic iron, copper, or molybdenum in lemurs with hepatocellular carcinoma and those without, suggesting that iron is not a key element in the pathogenesis of liver tumor formation.
  • Analysis of 22 serum samples from animals with and without liver tumors indicated no evidence of active infection with a hepadnavirus, the virus family that includes hepatitis B virus.
  • In conclusion, hepatocellular neoplasia is relatively common in captive prosimians, although previously suspected etiologies seem unlikely.
  • [MeSH-major] Carcinoma, Hepatocellular / veterinary. Lemur. Liver Neoplasms / veterinary. Monkey Diseases / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20147584.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Aramaki M, Kawano K, Sasaki A, Ohno T, Tahara K, Kai S, Iwashita Y, Kitano S: Hepatocellular carcinoma in young adults. Hepatogastroenterology; 2005 Nov-Dec;52(66):1795-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in young adults.
  • BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is uncommon in adolescent and young adult Japanese.
  • RESULTS: All patients were HBs antigen-positive patients, and most of them had relatively good liver function.
  • CONCLUSIONS: These results suggest that cases of HCC in young adults are rarely detected early because of their relatively good liver function despite their higher positive rate for HBs antigen.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / epidemiology. Liver Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Cross-Sectional Studies. Female. Hepatectomy / methods. Humans. Incidence. Japan / epidemiology. Liver Function Tests. Male. Neoplasm Staging. Prognosis. Risk Assessment. Sex Distribution. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334779.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


20. Fernández-Ruiz M, Guerra-Vales JM, Llenas-García J, Colina-Ruizdelgado F: [Hepatocellular carcinoma in the elderly: clinical characteristics, survival analysis, and prognostic indicators in a cohort of Spanish patients older than 75 years]. Rev Esp Enferm Dig; 2008 Oct;100(10):625-31
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatocellular carcinoma in the elderly: clinical characteristics, survival analysis, and prognostic indicators in a cohort of Spanish patients older than 75 years].
  • [Transliterated title] Carcinoma hepatocelular en el anciano: características clínicas, análisis de supervivencia y factores pronósticos en una cohorte de pacientes españoles mayores de 75 años.
  • AIMS: Hepatocellular carcinoma (HCC) remains poorly characterized in elderly patients with comorbid conditions, a fact that limits the clinical management of the disease.
  • CONCLUSIONS: The lower survival seen in elderly patients with HCC, beyond differences in tumor extension or liver failure, seems conditioned by the use of suboptimal treatment in this population.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / mortality. Liver Neoplasms / therapy. Survival Analysis
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Prognosis. Proportional Hazards Models. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19119788.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


21. Echejoh GO, Tanko MN, Manasseh AN, Ogala-Echejoh S, Ugoya SO, Mandong BM: Hepatocellular carcinoma in Jos, Nigeria. Niger J Med; 2008 Apr-Jun;17(2):210-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in Jos, Nigeria.
  • BACKGROUND: Hepatocellular carcinoma (HCC) is the most common abdominal malignancy, representing 80-90% of primary liver malignancies around the world.
  • RESULTS: A total of 71 cases of HCC (31.3% of 227 liver biopsies in the same period) were diagnosed within the 10-year period.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Nigeria / epidemiology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18686842.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


22. Bustíos Sánchez C, Díaz Ferrer J, Román Vargas R, Dávalos Moscol M, Zumaeta Villena E: [Clinical - Epidemiological characteristics of the Hepatocellular Carcinoma and treatment in the departament of digestive system diseases of the National Hospital "Eduardo Rebagliatti Martins" (HNERM) - ESSALUD]. Rev Gastroenterol Peru; 2009 Jan-Mar;29(1):17-23
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical - Epidemiological characteristics of the Hepatocellular Carcinoma and treatment in the departament of digestive system diseases of the National Hospital "Eduardo Rebagliatti Martins" (HNERM) - ESSALUD].
  • [Transliterated title] Características clínico - epidemiológicas del Carcinoma Hepatocelular y su tratamiento en el departamento del aparato digestivo del HNERM ES-SALUD.
  • Hepatocellular carcinoma (CHC) is one of the leading causes of worldwide cancer mortality.
  • [MeSH-major] Carcinoma, Hepatocellular. Liver Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Hospital Departments. Hospitals. Humans. Male. Middle Aged. Peru. Prospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424404.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down


23. Hu MG, Liu R, Luo Y: [Laparoscopic hepatectomy for hepatocellular carcinoma]. Zhonghua Wai Ke Za Zhi; 2008 Dec 1;46(23):1774-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic hepatectomy for hepatocellular carcinoma].
  • OBJECTIVE: To discuss the value of laparoscopic hepatectomy (LH) for hepatocellular carcinoma (HCC).
  • By 4 - 61 months of follow up, recurrence in liver occurred in 5 cases.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Laparoscopy. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094780.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


24. Lee HC, Kim M, Wands JR: Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci; 2006;11:1901-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wnt/Frizzled signaling in hepatocellular carcinoma.
  • The Wnt/Frizzled (FZD) signaling cascade is important for cell fate determination during embryonic development as well as maintaining tissue homeostasis in the adult.
  • In addition, hepatocellular carcinoma (HCC) is another tumor with frequent aberrant activation of beta-catenin signaling.
  • [MeSH-major] Adenomatous Polyposis Coli / metabolism. Carcinoma, Hepatocellular / metabolism. Frizzled Receptors / metabolism. Gene Expression Regulation, Neoplastic. Liver Neoplasms / embryology. Wnt Proteins / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Animals. Cell Lineage. Colorectal Neoplasms / metabolism. Humans. Ligands. Models, Biological. Mutation. Neoplasms / metabolism. Signal Transduction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16368566.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Grant] United States / NIAAA NIH HHS / AA / AA02666; United States / NIAAA NIH HHS / AA / AA20169; United States / NCI NIH HHS / CA / CA35711; United States / NCRR NIH HHS / RR / P20 RR 015578
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Frizzled Receptors; 0 / Ligands; 0 / Wnt Proteins; 0 / beta Catenin
  • [Number-of-references] 134
  •  go-up   go-down


25. Zuckermann M, Batignani G, Leo F, Tonelli F: [Surgical treatment of hepatocellular carcinoma: prognostic factors for long-term disease-free survival and tumor recurrence]. Suppl Tumori; 2005 May-Jun;4(3):S51-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of hepatocellular carcinoma: prognostic factors for long-term disease-free survival and tumor recurrence].
  • [Transliterated title] La terapia chirurgica del carcinoma epatocellulare: fattori prognostici per la sopravvivenza a lungo termine libera da malattia e la recidiva tumorale.
  • Hepatocellular carcinoma mainly develops in a cirrhotic liver; in the majority of the patients chronic hepatitis or cirrhosis are virus-related and/or postalcoholic.
  • Liver resection is the gold standard treatment when there is no multifocality of the tumor and liver disease is not advanced (patients with Child-Pugh A score, or B in selected cases).
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / mortality. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437898.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


26. Flemming P, Lehmann U, Steinemann D, Kreipe H, Wilkens L: [Hepatocellular adenoma. Malignancy potential and differentiation from hepatocellular carcinoma]. Pathologe; 2006 Jul;27(4):238-43
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatocellular adenoma. Malignancy potential and differentiation from hepatocellular carcinoma].
  • In contrast to hepatocellular carcinoma (HCC), very few molecular pathological studies have been carried out on hepatocellular adenoma (HCA).
  • A limitation of particular HCA in genetic and metabolic diseases, children, adult males, adenomatosis, and HCA-like tumors with known risk factors of HCC would seem pragmatically meaningful.
  • [MeSH-major] Adenoma / pathology. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16736176.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


27. Lee WS, Lee KW, Heo JS, Kim SJ, Choi SH, Kim YI, Joh JW: Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today; 2006;36(10):892-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
  • PURPOSE: Combined hepatocellular and cholangiocarcinoma (HCC-CC) is a rare primary hepatic neoplasm (PHN) with features of both hepatocellular and biliary differentiation.
  • We compared the outcome of hepatic resection in patients with HCC-CC, those with hepatocellular carcinoma (HCC), and those with cholangiocarcinoma (ICC).
  • The prevalence of underlying liver cirrhosis was significantly lower in the ICC group (7.8%) than in the HCC (49%) and HCC-CC (41.5%) groups (P < 0.0001).
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Follow-Up Studies. Hepatectomy. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998683.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


28. Romanque P, Piguet AC, Dufour JF: Targeting vessels to treat hepatocellular carcinoma. Clin Sci (Lond); 2008 Apr;114(7):467-77
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting vessels to treat hepatocellular carcinoma.
  • In adult life, it participates in normal tissue repair, wound healing, and cyclical growth of the corpus luteum and the endometrium.
  • The present review highlights the evidence for the role of angiogenesis in HCC (hepatocellular carcinoma) and discusses the increasing importance of inhibitors of angiogenesis in HCC therapy.
  • [MeSH-major] Carcinoma, Hepatocellular / blood supply. Liver Neoplasms / blood supply. Neovascularization, Pathologic / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18302534.001).
  • [ISSN] 1470-8736
  • [Journal-full-title] Clinical science (London, England : 1979)
  • [ISO-abbreviation] Clin. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; 0 / Vascular Endothelial Growth Factors; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 107
  •  go-up   go-down


29. Borzio M, Colloredo G, Pioltelli P, Quagliuolo M, Gruppo Epatologico Lombardo (GEL): Epidemiology and outcome of hepatocellular carcinoma in Lombardy. Dig Liver Dis; 2007 Nov;39(11):1011-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology and outcome of hepatocellular carcinoma in Lombardy.
  • BACKGROUND AND AIMS: Information on the impact of therapeutic strategies of hepatocellular carcinoma is still incomplete due to the lack of surveys involving primary-care centres.
  • PATIENTS AND METHODS: The Gruppo Epatologico Lombardo (GEL) carried out a study on 361 incident hepatocellular carcinoma observed from January to December 1998 in 22 hospitals in Lombardy.
  • Hepatocellular carcinoma was multifocal/diffuse (more than three nodules) in 91 (25%), less than three nodules in 86 (24%) and monofocal in 184 (51%) (</=3cm in 146).
  • As to the therapy: 145 hepatocellular carcinomas (40%) were untreated, 78 (22%) underwent percutaneous ethanol injection/radiofrequency ablation, 75 (20%) transarterial chemoembolization, 32 (9%) liver resection and 3 (0.8%) ortothopic liver transplantation (OLT).
  • CONCLUSION: This prospective, region-wide, cohort study showed that the characteristics of hepatocellular carcinoma in Lombardy (1998) do not differ from those reported in previous Italian surveys.
  • Although most hepatocellular carcinomas were discovered at a relatively early stage, a large part remained untreated and the overall prognosis was poor.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / epidemiology. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Italy / epidemiology. Male. Middle Aged. Prospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17936698.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


30. Sorlini M, Benini F, Cravarezza P, Romanelli G: Hypoglycemia, an atypical early sign of hepatocellular carcinoma. J Gastrointest Cancer; 2010 Sep;41(3):209-11
Hazardous Substances Data Bank. GLUCOSE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoglycemia, an atypical early sign of hepatocellular carcinoma.
  • BACKGROUND: Hypoglycemia is extremely uncommon as the first presentation of hepatocellular carcinoma, and it occurs predominantly as a paraneoplastic manifestation.
  • Abdominal ultrasonography and computed tomography revealed a big vascularized mass of 13 cm in diameter occupying most of the right lobe of the liver and an (18)F-fluoro-2-deoxy-D-glucose positron-emission tomography revealed a predominant uptake of glucose by the tumor mass.
  • CONCLUSIONS: These findings indicate that hepatocellular carcinoma-associated hypoglycemia may be due exclusively to increased glucose utilization by the tumor mass.
  • [MeSH-major] Carcinoma, Hepatocellular / complications. Hypoglycemia / etiology. Liver Neoplasms / complications. Paraneoplastic Syndromes / etiology
  • [MeSH-minor] Adult. Glucose / metabolism. Hepatitis B / complications. Humans. Male. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20204540.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] IY9XDZ35W2 / Glucose
  •  go-up   go-down


31. Pang YL, Zhang HG, Peng JR, Pang XW, Yu S, Xing Q, Yu X, Gong L, Yin YH, Zhang Y, Chen WF: The immunosuppressive tumor microenvironment in hepatocellular carcinoma. Cancer Immunol Immunother; 2009 Jun;58(6):877-86

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The immunosuppressive tumor microenvironment in hepatocellular carcinoma.
  • The present study was focused on analyzing the immune status within hepatocellular carcinoma.
  • In conclusion, the tumor microenvironment of hepatocellular carcinoma is featured by the presence of multiple immunosuppressive factors.
  • [MeSH-major] Carcinoma, Hepatocellular / immunology. Immunosuppressive Agents / metabolism. Lymphocytes, Tumor-Infiltrating / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD3 / immunology. Antigens, CD4 / immunology. Cell Proliferation. Female. Flow Cytometry. Forkhead Transcription Factors / metabolism. Humans. Interferon-gamma / metabolism. Interleukin-10 / immunology. Lymphocyte Activation. Male. Middle Aged. T-Lymphocytes / immunology. T-Lymphocytes / pathology. T-Lymphocytes, Regulatory / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941744.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD4; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Immunosuppressive Agents; 130068-27-8 / Interleukin-10; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


32. Park JW: [Hepatocellular carcinoma in Korea: introduction and overview]. Korean J Gastroenterol; 2005 Apr;45(4):217-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatocellular carcinoma in Korea: introduction and overview].
  • Hepatocellular carcinoma (HCC) is a highly malignant, generally fatal neoplasm arising from hepatocytes.
  • HCC accounts for over 80% of all primary liver cancers which ranks fourth among the organ-specific causes of cancer-related deaths worldwide.
  • Infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) or presence of liver cirrhosis are important risk factors for HCC development globally.
  • Recently, five year survival rate of primary liver cancer is 9.6% in Korea.
  • Such poor prognosis of HCC results from the late detection of cancer, an aggressive tumor biology and underlying chronic liver diseases.
  • Because almost eighty percent of HCC is diagnosed in late stage, we launched a nationwide surveillance program to screen high risk groups (HBV or HCV carriers or liver cirrhosis, over 40 years old) and formulated the Korean practice guideline for the diagnosis and treatment of HCC with special emphasis on advanced stage of HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Incidence. Korea / epidemiology. Male. Middle Aged. Prevalence. Risk Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15843747.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


33. Kao WY, Hung HH, Lu HC, Lin HC, Wu JC, Lee SD, Su CW: Hepatocellular carcinoma with presentation of budd-Chiari syndrome. J Chin Med Assoc; 2010 Feb;73(2):93-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma with presentation of budd-Chiari syndrome.
  • Computed tomography and magnetic resonance imaging confirmed hepatocellular carcinoma with inferior vena cava and right hepatic vein thrombosis.
  • Therefore, hepatocellular carcinoma with Budd-Chiari syndrome was diagnosed.
  • Although it is relatively rare, clinicians should be aware of hepatocellular carcinoma with Budd-Chiari syndrome when leg edema occurs without hypoalbuminemia in patients with chronic hepatitis B, because these patients are in the high-risk group for developing hepatocellular carcinoma.
  • [MeSH-major] Budd-Chiari Syndrome / etiology. Carcinoma, Hepatocellular / complications. Liver Neoplasms / complications
  • [MeSH-minor] Adult. Edema / etiology. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Budd-Chiari Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20171589.001).
  • [ISSN] 1728-7731
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


34. Freitas AC, Parolin MB, Stadnik L, Coelho JC: [Hepatocellular carcinoma: impact of waiting list and pre-operative treatment strategies on survival of cadaveric liver transplantation in pre-MELD era in one center in Brazil]. Arq Gastroenterol; 2007 Jul-Sep;44(3):189-94
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatocellular carcinoma: impact of waiting list and pre-operative treatment strategies on survival of cadaveric liver transplantation in pre-MELD era in one center in Brazil].
  • [Transliterated title] Carcinoma hepatocelular: impacto do tempo em lista e das formas de tratamento pré-operatório na sobrevida do transplante de fígado cadavérico na era pré-MELD em um centro no Brasil.
  • BACKGROUND: Liver transplantation is the main treatment option for hepatocellular carcinoma in patients with cirrhosis.
  • AIM: Three months and 3 years survival were analysed in patients with cirrhosis and hepatocellular carcinoma and in patients with only cirrhosis.
  • METHODS: Charts of patients subjected to cadaveric liver transplantation at the Clinical Hospital of the Federal University of Paraná, Curitiba, PR, Brazil, between January 5th of 2001 and February 17th of 2006 were reviewed.
  • Patients were divided into two groups for 3 months and 1 year survival analysis: cirrhosis and hepatocellular carcinoma and cirrhosis only.
  • RESULTS: One hundred and forty six liver transplantation patients were analysed: 75 were excluded because of incomplete data and 71 were included.
  • Patients with hepatocellular carcinoma (n = 12) presented 3 months and 1 year survivals of 100%.
  • These rates were significantly higher than those of patients without hepatocellular carcinoma (n = 59; 72,8% and 69,4%).
  • Mean MELD score, mean Child-Pugh score and mean number of red blood cells transfused were significantly higher in patients without hepatocellular carcinoma.
  • The rate of Child-Pugh A and hepatitis C was higher in patients with hepatocellular carcinoma.
  • CONCLUSION: Patients with cirrhosis and hepatocellular carcinoma presented better 3 months and 1 year survival rates than patients with only cirrhosis.
  • This is possibly due to an early stage of cirrhosis at transplantation of patients with hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Cirrhosis / surgery. Liver Neoplasms / surgery. Liver Transplantation / statistics & numerical data. Waiting Lists
  • [MeSH-minor] Adult. Brazil. Female. Humans. Male. Middle Aged. Patient Selection. Preoperative Care / methods. Retrospective Studies. Severity of Illness Index. Survival Analysis

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arq Gastroenterol. 2007 Jul-Sep;44(3):187-8 [18060268.001]
  • (PMID = 18060269.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


35. Kure S, Kaneko T, Takeda S, Inoue S, Nakao A: The feasibility of Makuuchi criterion for resection of hepatocellular carcinoma. Hepatogastroenterology; 2007 Jan-Feb;54(73):234-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The feasibility of Makuuchi criterion for resection of hepatocellular carcinoma.
  • BACKGROUND/AIMS: The Makuuchi criterion was proposed to select for the appropriate hepatectomy in an impaired liver.
  • METHODOLOGY: We conducted our study on 471 patients with hepatocellular carcinoma, resected from January 1986 to April 2004.
  • Blood loss in patients with postoperative liver failure was also greater than in others, both in group 1 (2692 +/- 292 mL vs. 1146 +/- 106 mL: P < 0.0002) and in group 2 (2968 +/- 335 mL vs. 1538 +/- 265 mL: P = 0.004).
  • CONCLUSIONS: Our study showed Makuuchi criterion is helpful for a safe hepatectomy for hepatocellular carcinoma.
  • If inconsistent with it, 2172 mL and 1538 mL blood loss are considered permissible upper limits to avoid operative death and liver failure, respectively.
  • [MeSH-major] Algorithms. Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Loss, Surgical / statistics & numerical data. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419267.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


36. Centers for Disease Control and Prevention (CDC): Hepatocellular carcinoma - United States, 2001-2006. MMWR Morb Mortal Wkly Rep; 2010 May 7;59(17):517-20
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma - United States, 2001-2006.
  • Liver cancer, primarily hepatocellular carcinoma (HCC), is the third leading cause of death from cancer worldwide and the ninth leading cause of cancer deaths in the United States.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Incidence. Infant. Male. Middle Aged. SEER Program. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20448528.001).
  • [ISSN] 1545-861X
  • [Journal-full-title] MMWR. Morbidity and mortality weekly report
  • [ISO-abbreviation] MMWR Morb. Mortal. Wkly. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Mokhles M, Abd El Wahhab MA, Tawfik M, Ezzat W, Gamil K, Ibrahim M: Detection of aflatoxin among hepatocellular carcinoma patients in Egypt. Pak J Biol Sci; 2007 May 1;10(9):1422-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of aflatoxin among hepatocellular carcinoma patients in Egypt.
  • Present study comprised (46) Hepatocellular Carcinoma (HCC) patients with mean age (56.28 +/- 8.08), 30 males and 16 females, (12) cirrhotic patients with mean age (47.83 +/- 18.20), 7 males and 5 females and (12) sex and age matched healthy controls.
  • All were exposed to, liver function tests, abdominal ultrasonography and detection of Aflatoxin metabolite M1 in serum and urine by means of the reverse phase HPLC device.
  • [MeSH-major] Aflatoxin M1. Carcinoma, Hepatocellular. Liver Neoplasms. Poisons
  • [MeSH-minor] Adult. Aged. Chromatography, High Pressure Liquid. Egypt. Female. Humans. Liver Cirrhosis / blood. Liver Cirrhosis / urine. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069952.001).
  • [ISSN] 1028-8880
  • [Journal-full-title] Pakistan journal of biological sciences : PJBS
  • [ISO-abbreviation] Pak. J. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Poisons; 6795-23-9 / Aflatoxin M1
  •  go-up   go-down


38. Herr I, Groth A, Schemmer P, Büchler MW: Adult stem cells in progression and therapy of hepatocellular carcinoma. Int J Cancer; 2007 Nov 1;121(9):1875-82
Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult stem cells in progression and therapy of hepatocellular carcinoma.
  • Hepatocellular carcinoma is one of the most aggressive solid tumours associated with poor prognosis.
  • The medical community is currently experiencing a wave of enthusiasm for clinical trials, in which adult stem/progenitor cells are used for liver regeneration.
  • Stem cells may contribute to fibrosis or give rise to hepatic cancer stem cells as a source of hepatocellular carcinoma.
  • This review outlines the current state of knowledge in progression of liver disease and highlights the function of adult stem cells in disease and therapy.
  • [MeSH-major] Adult Stem Cells / transplantation. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / therapy
  • [MeSH-minor] Animals. Cell Differentiation. Disease Progression. Humans. Regeneration

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17685426.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 79
  •  go-up   go-down


39. Kurogi M, Nakashima O, Miyaaki H, Fujimoto M, Kojiro M: Clinicopathological study of scirrhous hepatocellular carcinoma. J Gastroenterol Hepatol; 2006 Sep;21(9):1470-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological study of scirrhous hepatocellular carcinoma.
  • BACKGROUND AND AIMS: Scirrhous hepatocellular carcinoma (SHCC) is characterized by diffuse fibrosis of the tumor, however, its clinicopathological features are not fully clarified.
  • On diagnostic imagings, SHCC was frequently misdiagnosed as cholangiocarcinoma (CC), combined HCC-CC or metastatic carcinoma.
  • The majority of SHCC (88%) were located close to the liver capsule.
  • SHCC was characterized by stellate fibrosis (84%), no encapsulation (100%), no necrosis and hemorrhage (100%), intratumoral portal tracts (80%), remarkable lymphocyte infiltration (84%), clear cell change (84%), and hyaline bodies (52%).
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / physiopathology. Liver Neoplasms / pathology. Liver Neoplasms / physiopathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Liver Function Tests. Male. Middle Aged. Survival Rate. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16911695.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


40. Su R, Li Z, Li H, Song H, Bao C, Wei J, Cheng L: Grp78 promotes the invasion of hepatocellular carcinoma. BMC Cancer; 2010;10:20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grp78 promotes the invasion of hepatocellular carcinoma.
  • But the role of Grp78 in the invasion of human hepatocellular carcinoma has not been reported.
  • In this article, we examined if Grp78 was associated with the invasion of hepatocellular carcinoma and explored the possible underlying mechanism.
  • METHODS: The Grp78 and FAK expression levels in 44 patients with hepatocellular carcinoma were examined using immunohistochemistry.
  • Cell spreading was determined by cell spreading assay, and quantitatively measured by Orisis software HUG.
  • RESULTS: Grp78 expression levels in 44 patients with hepatocellular carcinoma were negatively correlated with tumor grading, and positively correlated with portal invasion and intra-hepatic invasion.
  • Overexpression of Grp78 in SMMC7721 cells promoted the invasion of cancer cells in vitro and in vivo, and this increase in tumor cell invasion was blocked by Grp78 siRNA knockdown.
  • Our results also revealed that overexpression of Grp78 in SMMC7721 cells accelerated the process of cell spreading and promoted lamellipodia formation.
  • Our results also revealed that Grp78 overexpression in SMMC7721 cells decreased RhoA-GTP level, and Grp78 siRNA knockdown rescued RhoA-GTP level in Grp78 overexpressing cells, indicating Grp78 inhibited RhoA activity in hepatocellular carcinoma cells.
  • CONCLUSION: Grp78 promoted the invasion of hepatocellular carcinoma both in vitro and in vivo.
  • Overexpression of Grp78 in hepatocellular carcinoma cells enhanced the activation and activity of FAK which negatively regulated Rock kinase activity by promoting the phosphorylation of p190RhoGAP.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Heat-Shock Proteins / metabolism. Liver Neoplasms / pathology
  • [MeSH-minor] Actins / chemistry. Adult. Aged. Animals. Cell Line, Tumor. Chick Embryo. Cytoskeleton / metabolism. Female. Guanine Nucleotide Exchange Factors / metabolism. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Phosphorylation. RNA, Small Interfering / metabolism. Repressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2001 May;107(10):1263-73 [11375416.001]
  • [Cites] Genome Biol. 2009;10(3):213 [19291272.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7083-92 [12460930.001]
  • [Cites] Cell. 2004 Jan 23;116(2):167-79 [14744429.001]
  • [Cites] Nat Cell Biol. 2004 Feb;6(2):154-61 [14743221.001]
  • [Cites] Nucleic Acids Res. 2004;32(3):936-48 [14769950.001]
  • [Cites] Curr Opin Genet Dev. 2004 Feb;14(1):92-101 [15108811.001]
  • [Cites] Mol Biol Cell. 1999 Aug;10(8):2481-91 [10436006.001]
  • [Cites] Science. 1999 Aug 6;285(5429):895-8 [10436159.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jan;6(1):56-68 [15688067.001]
  • [Cites] Radiographics. 2005 Oct;25 Suppl 1:S3-23 [16227495.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 19;97(20):1532-8 [16234567.001]
  • [Cites] Clin Chim Acta. 2006 Feb;364(1-2):308-15 [16182273.001]
  • [Cites] J Biol Chem. 2006 Jan 27;281(4):2296-305 [16308318.001]
  • [Cites] Curr Opin Cell Biol. 2006 Oct;18(5):516-23 [16919435.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11424-31 [17145889.001]
  • [Cites] Clin Exp Metastasis. 2006;23(7-8):401-10 [17187227.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3496-9 [17440054.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):498-505 [18199545.001]
  • [Cites] J Cell Physiol. 2008 Jun;215(3):627-35 [18064632.001]
  • [Cites] Hum Pathol. 2008 Jul;39(7):1042-9 [18482745.001]
  • [Cites] Carcinogenesis. 2008 Jul;29(7):1299-305 [18515282.001]
  • [Cites] Oncogene. 2008 Dec 4;27(53):6782-9 [18776923.001]
  • [Cites] Biochim Biophys Acta. 2009 Apr;1795(2):137-51 [19162129.001]
  • [Cites] Trends Biochem Sci. 2001 Aug;26(8):504-10 [11504627.001]
  • (PMID = 20082722.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ARHGAP35 protein, human; 0 / Actins; 0 / Guanine Nucleotide Exchange Factors; 0 / Heat-Shock Proteins; 0 / RNA, Small Interfering; 0 / Repressor Proteins; 0 / molecular chaperone GRP78
  • [Other-IDs] NLM/ PMC2821360
  •  go-up   go-down


41. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C: Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology; 2008 Jul;48(1):137-45
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004.
  • Upward trends in mortality from hepatocellular carcinoma (HCC) were recently reported in the United States and Japan.
  • In the early 2000s, among countries allowing distinction between HCC and other liver cancers, the highest HCC rates in men were in France (6.8/100,000), Italy (6.7), and Switzerland (5.9), whereas the lowest ones were in Norway (1.0), Ireland (0.8), and Sweden (0.7).
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Age Distribution. Demography. Europe / epidemiology. Female. Humans. Male. Middle Aged. Mortality / trends. Sex Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatology. 2009 Jan;49(1):336; author reply 336-7 [19035339.001]
  • (PMID = 18537177.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Stipa F, Yoon SS, Liau KH, Fong Y, Jarnagin WR, D'Angelica M, Abou-Alfa G, Blumgart LH, DeMatteo RP: Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer; 2006 Mar 15;106(6):1331-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with fibrolamellar hepatocellular carcinoma.
  • BACKGROUND: Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare variant of hepatocellular carcinoma, has distinct pathologic features, and typically occurs in young patients without underlying hepatitis or cirrhosis.
  • Twenty-eight patients with primary disease underwent complete gross resection, and 13 patients were unresectable.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Hepatectomy. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Fibrolamellar carcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16475212.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Park WS, Cho YG, Kim CJ, Song JH, Lee YS, Kim SY, Nam SW, Lee SH, Yoo NJ, Lee JY: Hypermethylation of the RUNX3 gene in hepatocellular carcinoma. Exp Mol Med; 2005 Aug 31;37(4):276-81
Hazardous Substances Data Bank. AZACITIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of the RUNX3 gene in hepatocellular carcinoma.
  • To elucidate the potential etiological role of the RUNX3 gene in the development of hepatocellular carcinoma (HCC), we have analyzed the methylation status of 5' CpG island of the RUNX3 gene in a series of 73 HCC tissues and 11 liver cell lines.
  • Expectedly, promoter methylation of RUNX3 gene was found in 2 (2.7%) of 73 corresponding normal liver, whereas 30 (41.1%) of 73 HCCs and 4 (40%) of 10 liver cancer cell lines showed hypermethylation of the gene, respectively.
  • There was no significant difference between promoter hypermethylaion and clinicopathologic parameters of primary HCC samples, including histologic grade, microvascular invasion, and clinical stage.
  • Interestingly, demethylating agent 5-aza-2-deoxycytidine induced reactivation and more potent expression of RUNX3 gene in HCC cell lines.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. DNA Methylation. DNA, Neoplasm / metabolism. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Female. Humans. Male. Middle Aged. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155404.001).
  • [ISSN] 1226-3613
  • [Journal-full-title] Experimental & molecular medicine
  • [ISO-abbreviation] Exp. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


44. Chrzanowska A, Krawczyk M, Barańczyk-Kuźma A: Changes in arginase isoenzymes pattern in human hepatocellular carcinoma. Biochem Biophys Res Commun; 2008 Dec 12;377(2):337-40
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in arginase isoenzymes pattern in human hepatocellular carcinoma.
  • Hepatocellular carcinoma (HCC) is one of the most common tumors worldwide affecting preferentially patients with liver cirrhosis.
  • The studies were performed on tissues obtained during surgery from 50 patients with HCC, 40 with liver cirrhosis and 40 control livers.
  • Isoenzymes AI (so-called liver-type arginase) and AII (extrahepatic arginase) were identified by Western blotting in all studied tissues, however the amount of AI, as well as the expression of AI-mRNA were lower in HCC, in comparison with normal liver, and those of AII were significantly higher.
  • Thus, both arginase isoenzymes seem to participate in liver cancerogenesis.
  • [MeSH-major] Arginase / metabolism. Arginine / metabolism. Carcinoma, Hepatocellular / enzymology. Liver Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Blotting, Western. Cell Transformation, Neoplastic. Enzyme Activation. Female. Humans. Isoenzymes / metabolism. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18831962.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; 94ZLA3W45F / Arginine; EC 3.5.3.1 / Arginase
  •  go-up   go-down


45. Yuen MF, Hou JL, Chutaputti A, Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma: Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol; 2009 Mar;24(3):346-53
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in the Asia pacific region.
  • Primary liver cancer, particularly hepatocellular carcinoma (HCC) remains a significant disease worldwide.
  • In spite of advances in surgery, liver transplantation and newer pharmaco/biological therapies, the survival rate has improved only slightly over recent decades, and this could be attributable to earlier diagnosis ('lead-time bias').
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Factors. Asia / epidemiology. Asian Continental Ancestry Group. Female. Hepatitis B, Chronic / complications. Hepatitis B, Chronic / epidemiology. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / epidemiology. Humans. Incidence. Male. Middle Aged. Odds Ratio. Prevalence. Prognosis. Risk Assessment. Risk Factors. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19220670.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Australia
  • [Number-of-references] 35
  • [Investigator] Farrell GC; Chan HL; Yuen MF; Amarapurkar DN; Chutaputti A; Fan JG; Hou JL; Han KH; Kao JH; Lim SG; Mohamed R; Sollano J; Ueno Y
  •  go-up   go-down


46. Lee JG, Choi SB, Kim KS, Choi JS, Lee WJ, Kim BR: Central bisectionectomy for centrally located hepatocellular carcinoma. Br J Surg; 2008 Aug;95(8):990-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central bisectionectomy for centrally located hepatocellular carcinoma.
  • BACKGROUND: Central bisectionectomy, which involves the removal of the central hepatic segments (IVA, IVB, V, VIII) for hepatocellular carcinoma (HCC), is performed to reduce the volume of resected liver and to overcome the problem of insufficient future residual volume.
  • CONCLUSION: Although biliary complications occur somewhat frequently, central bisectionectomy in centrally located HCC can be performed safely to preserve liver volume.
  • [MeSH-major] Bile Ducts / injuries. Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver / pathology. Liver Neoplasms / surgery. Postoperative Complications / etiology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 18574845.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


47. Zacharoulis D, Hatzitheofilou C, Athanasiou E, Zacharoulis S: Antiangiogenic strategies in hepatocellular carcinoma: current status. Expert Rev Anticancer Ther; 2005 Aug;5(4):645-56
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiangiogenic strategies in hepatocellular carcinoma: current status.
  • Hepatocellular carcinoma is a leading cause of cancer death worldwide in both adult and pediatric patients.
  • Angiogenesis, the formation of new blood vessels, is an essential component of hepatocellular carcinoma biology.
  • Innovative approaches such as targeting the nontransformed, less resistant, tumor-supporting endothelial cells are currently under investigation in hepatocellular carcinoma.
  • This review will focus on the current knowledge of the pathophysiology of hepatocellular carcinoma angiogenesis, as well as the reported data with angiogenesis inhibitors against hepatocellular carcinoma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Hepatocellular / blood supply. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / blood supply. Liver Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16111465.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  • [Number-of-references] 121
  •  go-up   go-down


48. Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, Shiratori K: Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol; 2009;44 Suppl 19:89-95
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.
  • BACKGROUND: There have been few reports on hepatocellular carcinoma (HCC) in nonalcoholic steatohepatitis (NASH) and the natural history of NASH.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Fatty Liver / pathology. Liver Neoplasms / etiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Cohort Studies. Female. Humans. Liver Cirrhosis / complications. Liver Cirrhosis / pathology. Logistic Models. Male. Middle Aged. Proportional Hazards Models. Prospective Studies. Risk Factors. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148800.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


49. Shi M, Guo RP, Zhang CQ, Zhong C, Lin XJ, Li JQ: [Expression of CXCR3 in hepatocellular carcinoma]. Ai Zheng; 2006 Oct;25(10):1232-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of CXCR3 in hepatocellular carcinoma].
  • This study was to investigate the expression of CXCR3, a chemokine receptor, and its correlation to clinicopathologic features of hepatocellular carcinoma (HCC).
  • METHODS: CXCR3 mRNA expression in 7 human HCC cell lines, 18 normal liver tissues and 64 pairs of HCC tissues and adjacent liver tissues was detected by reverse transcription-polymerase chain reaction (RT-PCR) and real-time quantitative PCR; CXCR3 protein expression was detected by immunohistochemistry.
  • RESULTS: CXCR3 mRNA was expressed in 2 HCC cell lines (MHCC97-H and MHCC97-L) with metastatic potential, but not in 5 HCC cell lines without metastatic potential.
  • However, the staining of CXCR3 protein was not detected in 4 HCC cell lines without metastatic potential; only weak staining was detected in HepG-2 cells.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Receptors, CXCR3 / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Humans. Liver / metabolism. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Recurrence, Local. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. beta 2-Microglobulin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059766.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCR3 protein, human; 0 / RNA, Messenger; 0 / Receptors, CXCR3; 0 / beta 2-Microglobulin
  •  go-up   go-down


50. van Zijl F, Zulehner G, Petz M, Schneller D, Kornauth C, Hau M, Machat G, Grubinger M, Huber H, Mikulits W: Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol; 2009 Oct;5(8):1169-79
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial-mesenchymal transition in hepatocellular carcinoma.
  • The transition of epithelial cells to a mesenchymal phenotype is of paramount relevance for embryonic development and adult wound healing.
  • During the past decade, the epithelial-mesenchymal transition (EMT) has been increasingly recognized to occur during the progression of various carcinomas such as hepatocellular carcinoma (HCC).
  • Here, we focus on EMT in both experimental liver models and human HCC, emphasizing the underlying molecular mechanisms which show partial recurrence of embryonic programs such as TGF-beta and Wnt/ beta-catenin signaling, including collaboration with hepatitis viruses.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Cell Differentiation / physiology. Cell Transformation, Neoplastic / pathology. Epithelium / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Animals. Cell Dedifferentiation / physiology. Humans. Mesoderm / pathology. Metaplasia

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 Jul 15;65(14):5991-5; discussion 5995 [16024595.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] J Biol Chem. 2007 Jul 27;282(30):22089-101 [17513865.001]
  • [Cites] J Biol Chem. 2007 Aug 10;282(32):23337-47 [17562716.001]
  • [Cites] Exp Cell Res. 2008 Jan 1;314(1):143-52 [17949712.001]
  • [Cites] Hepatology. 2007 Dec;46(6):1801-9 [17948258.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):321-9 [12724730.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Aug;4(8):657-65 [12923528.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6725-38 [14555986.001]
  • [Cites] Mutat Res. 2004 Jan;566(1):9-20 [14706509.001]
  • [Cites] Hepatology. 2004 Mar;39(3):628-34 [14999681.001]
  • [Cites] Hepatology. 2004 Apr;39(4):1038-47 [15057908.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):836-47 [15459664.001]
  • [Cites] Cancer. 1990 Nov 15;66(10):2174-9 [2171748.001]
  • [Cites] EMBO J. 1997 Feb 3;16(3):495-503 [9034332.001]
  • [Cites] Science. 1997 Apr 4;276(5309):60-6 [9082986.001]
  • [Cites] Am J Pathol. 1997 Nov;151(5):1273-80 [9358753.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):931-42 [15705598.001]
  • [Cites] Oncogene. 2005 Jun 30;24(28):4580-7 [15856020.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1375-83 [16285938.001]
  • [Cites] Front Biosci. 2006;11:1901-15 [16368566.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]
  • [Cites] Oncogene. 2001 Oct 25;20(48):7104-9 [11704835.001]
  • [Cites] J Cell Sci. 2002 Mar 15;115(Pt 6):1189-202 [11884518.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):46-54 [11900251.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Mol Cancer Res. 2002 Nov;1(1):68-78 [12496370.001]
  • [Cites] Hepatology. 2008 Mar;47(3):919-28 [18275073.001]
  • [Cites] Oncogene. 2008 Mar 13;27(12):1749-58 [17891174.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2391-9 [18381447.001]
  • [Cites] J Clin Invest. 2008 Apr;118(4):1354-66 [18357344.001]
  • [Cites] Hepatology. 2008 May;47(5):1557-66 [18318443.001]
  • [Cites] Gastroenterology. 2008 May;134(6):1655-69 [18471545.001]
  • [Cites] Cell. 2008 May 16;133(4):704-15 [18485877.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Gastroenterology. 2008 Aug;135(2):642-59 [18602923.001]
  • [Cites] Hepatology. 2008 Sep;48(3):909-19 [18712785.001]
  • [Cites] Hepatology. 2008 Oct;48(4):1312-27 [18821591.001]
  • [Cites] World J Gastroenterol. 2008 Oct 7;14(37):5665-73 [18837082.001]
  • [Cites] Clin J Oncol Nurs. 2008 Oct;12(5):759-66 [18842532.001]
  • [Cites] Semin Liver Dis. 2008 Nov;28(4):370-9 [18956293.001]
  • [Cites] PLoS One. 2009;4(2):e4355 [19190755.001]
  • [Cites] Oncogene. 2009 Feb 5;28(5):638-50 [19015638.001]
  • [Cites] Hepatology. 2009 Mar;49(3):839-50 [19115199.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):265-73 [19262571.001]
  • [Cites] Hepatology. 2009 May;49(5):1571-82 [19296470.001]
  • [Cites] Hepatology. 2009 Jun;49(6):2031-43 [19274752.001]
  • [Cites] Biochim Biophys Acta. 2009 Jul;1790(7):663-70 [18848602.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3787-800 [16799620.001]
  • [Cites] Oncogene. 2006 May 25;25(22):3170-85 [16607286.001]
  • [Cites] Oncogene. 2008 Sep 18;27(42):5578-89 [18504433.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3818-22 [16799623.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):674-87 [16929323.001]
  • [Cites] J Cell Physiol. 2006 Nov;209(2):560-7 [16883581.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5369-76 [17000670.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9948-56 [17047057.001]
  • [Cites] FASEB J. 2006 Nov;20(13):2291-301 [17077306.001]
  • [Cites] Semin Liver Dis. 2007 Feb;27(1):55-76 [17295177.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):539-48 [17332881.001]
  • [Cites] Curr Opin Cell Biol. 2007 Apr;19(2):150-8 [17306971.001]
  • [Cites] Oncogene. 2007 May 17;26(23):3395-405 [17130832.001]
  • [Cites] World J Gastroenterol. 2007 Apr 28;13(16):2271-82 [17511024.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2542-56 [17570225.001]
  • (PMID = 19852728.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / FWF/ F 2801; Austria / Austrian Science Fund FWF / / FWF/ F 2806; Austria / Austrian Science Fund FWF / / FWF/ P 19598
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 66
  • [Other-IDs] NLM/ PMC2963061; NLM/ UKMS32703
  •  go-up   go-down


51. Ng KT, Man K, Sun CK, Lee TK, Poon RT, Lo CM, Fan ST: Clinicopathological significance of homeoprotein Six1 in hepatocellular carcinoma. Br J Cancer; 2006 Oct 23;95(8):1050-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of homeoprotein Six1 in hepatocellular carcinoma.
  • Tumour recurrence and metastases of hepatocellular carcinoma (HCC) after hepatectomy are the major obstacles of long-term survival.
  • Seventy-two pairs of RNA and 103 pairs of protein from tumour and adjacent nontumour liver tissues of HCC patients were examined.
  • About 85 and 60% of HCC tumour tissues were found to overexpress Six1 mRNA and protein, respectively, compared with nontumour liver tissues.
  • No Six1 protein was detected in HCC nontumour liver tissues and normal liver tissues.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Homeodomain Proteins / genetics. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Blotting, Western. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12608-13 [9770533.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2668-75 [15805264.001]
  • [Cites] Semin Liver Dis. 2005;25(2):181-200 [15918147.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1982-9 [16488997.001]
  • [Cites] Genes Dev. 1999 Dec 15;13(24):3171-8 [10617565.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):22245-54 [10801845.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1B):657-62 [11299822.001]
  • [Cites] World J Gastroenterol. 2001 Oct;7(5):630-6 [11819844.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2181-90 [12057921.001]
  • [Cites] Development. 2003 May;130(10):2239-52 [12668636.001]
  • [Cites] Development. 2003 Jul;130(14):3085-94 [12783782.001]
  • [Cites] Development. 2003 Sep;130(17):3989-4000 [12874121.001]
  • [Cites] Hepatology. 2003 Dec;38(6):1540-51 [14647065.001]
  • [Cites] Development. 2004 Feb;131(3):551-62 [14695375.001]
  • [Cites] Br J Surg. 2004 Feb;91(2):131-3 [14760656.001]
  • [Cites] Nat Med. 2004 Feb;10(2):175-81 [14704789.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S39-45 [14762838.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6478-83 [15123840.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16 [15508102.001]
  • [Cites] Development. 1995 Mar;121(3):693-705 [7720577.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):985-90 [9500460.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1253-7 [10217098.001]
  • (PMID = 17008870.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / RNA, Messenger; 0 / SIX1 protein, human
  • [Other-IDs] NLM/ PMC2360701
  •  go-up   go-down


52. Otegbayo JA, Atalabi OM, Yakubu A: Clinicoradiologic and sonographic patterns of metastasis in hepatocellular carcinoma. J Natl Med Assoc; 2006 Oct;98(10):1620-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicoradiologic and sonographic patterns of metastasis in hepatocellular carcinoma.
  • Hepatocellular carcinoma (HCC) is usually diagnosed at an advanced stage, when little remedy could be offered.
  • [MeSH-major] Carcinoma, Hepatocellular. Liver Neoplasms
  • [MeSH-minor] Adult. Cross-Sectional Studies. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Prospective Studies. Radiography, Thoracic

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2000;35(3):240-4 [10755695.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5):450-9 [11685738.001]
  • [Cites] Taehan Kan Hakhoe Chi. 2002 Jun;8(2):218-22 [12499808.001]
  • [Cites] Eur Radiol. 2002 Dec;12 Suppl 3:S70-3 [12522608.001]
  • [Cites] Niger Med J. 1978 Mar-Apr;8(2):108-11 [645212.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8041-7 [16258102.001]
  • [Cites] Chest. 1984 Sep;86(3):430-4 [6088178.001]
  • [Cites] Ital J Gastroenterol. 1992 Feb;24(2):95-9 [1315595.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jan;168(1):280-1 [8976965.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):798-9 [10072416.001]
  • [Cites] Afr J Med Med Sci. 2005 Mar;34(1):51-4 [15971554.001]
  • [Cites] Int J Cancer. 2005 Nov 10;117(3):506-9 [15906357.001]
  • [Cites] J Natl Cancer Inst. 1980 May;64(5):1263-72 [6767876.001]
  • (PMID = 17052052.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2569757
  •  go-up   go-down


53. Katoh H, Shibata T, Kokubu A, Ojima H, Fukayama M, Kanai Y, Hirohashi S: Epigenetic instability and chromosomal instability in hepatocellular carcinoma. Am J Pathol; 2006 Apr;168(4):1375-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic instability and chromosomal instability in hepatocellular carcinoma.
  • The aim of this study was to clarify the association between the epigenetic instability phenotype and the chromosomal instability phenotype in primary hepatocellular carcinoma (HCC).
  • Sixty primary HCC tumors were examined.
  • Hepatitis virus infection in the background liver was significantly associated with these instability phenotypes.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Chromosomal Instability / genetics. Liver Neoplasms / genetics. Phenotype
  • [MeSH-minor] Adult. Aged. CpG Islands. DNA Methylation. Epigenesis, Genetic. Female. Hepatitis A / complications. Hepatitis A / virology. Hepatitis B / complications. Hepatitis B / virology. Humans. Male. Middle Aged. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2005 Aug;37(8):899-905 [16007089.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2719-22 [8504410.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6617-25 [16007161.001]
  • [Cites] J Hepatol. 2005 Nov;43(5):863-74 [16139920.001]
  • [Cites] Cancer Lett. 2000 Jan 1;148(1):73-80 [10680595.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1835-9 [10766168.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5021-6 [11016622.001]
  • [Cites] Hepatology. 2000 Nov;32(5):970-9 [11050047.001]
  • [Cites] J Gastroenterol. 2000;35(10):727-34 [11063215.001]
  • [Cites] Nature. 1997 Apr 10;386(6625):623-7 [9121588.001]
  • [Cites] Oncogene. 1999 Jan 21;18(3):789-95 [9989830.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):988-93 [15573120.001]
  • [Cites] Nucleic Acids Res. 2005;33(9):2952-61 [15911630.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3948-56 [15883410.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):853-62 [16007088.001]
  • [Cites] Hepatology. 2001 Mar;33(3):561-8 [11230735.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3573-7 [11325821.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):787-94 [11891177.001]
  • [Cites] J Natl Cancer Inst. 2002 May 15;94(10):755-61 [12011226.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Hepatology. 2002 Aug;36(2):427-32 [12143052.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):339-46 [12149612.001]
  • [Cites] Ann Oncol. 2002 Nov;13(11):1699-716 [12419742.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15584-9 [12438687.001]
  • [Cites] Science. 2003 Apr 18;300(5618):455 [12702868.001]
  • [Cites] Science. 2003 Apr 18;300(5618):489-92 [12702876.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1101-7 [12937151.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1371-8 [14507645.001]
  • [Cites] Curr Mol Med. 2003 Sep;3(6):573-88 [14527088.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3741-7 [15172977.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):559-63 [15245590.001]
  • [Cites] EMBO J. 1988 Feb;7(2):419-26 [3366119.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2715-8 [8389241.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6177-85 [16144918.001]
  • (PMID = 16565510.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2216681
  •  go-up   go-down


54. Hasegawa K, Kokudo N, Imamura H, Matsuyama Y, Aoki T, Minagawa M, Sano K, Sugawara Y, Takayama T, Makuuchi M: Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg; 2005 Aug;242(2):252-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of anatomic resection for hepatocellular carcinoma.
  • OBJECTIVES: To evaluate the prognostic impact of anatomic versus nonanatomic resection on the patients' survival after resection of a single hepatocellular carcinoma (HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / mortality. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1999 Aug;86(8):1032-8 [10460639.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):322-30 [10077043.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1151-8 [10506698.001]
  • [Cites] Arch Surg. 1999 Oct;134(10):1124-30 [10522859.001]
  • [Cites] Presse Med. 1954 May 5;62(33):709-12 [13177441.001]
  • [Cites] Arch Surg. 1999 Sep;134(9):984-92 [10487594.001]
  • [Cites] J Am Coll Surg. 1998 Nov;187(5):471-81 [9809562.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):922-8 [11485528.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):944-52 [11592763.001]
  • [Cites] Surgery. 2002 Mar;131(3):311-7 [11894036.001]
  • [Cites] Br J Cancer. 2003 Aug 18;89(4):605-11 [12915864.001]
  • [Cites] Ann Surg. 2003 Nov;238(5):703-10 [14578733.001]
  • [Cites] Ann Surg. 1984 Jan;199(1):51-6 [6318677.001]
  • [Cites] Surg Gynecol Obstet. 1985 Oct;161(4):346-50 [2996162.001]
  • [Cites] Semin Liver Dis. 1986 Aug;6(3):259-66 [3022387.001]
  • [Cites] Ann Surg. 1989 Jul;210(1):20-3 [2662923.001]
  • [Cites] Cancer. 1990 Mar 1;65(5):1104-10 [2154320.001]
  • [Cites] Am J Surg. 1991 Jun;161(6):677-82 [1650535.001]
  • [Cites] Ann Surg. 1991 Aug;214(2):114-7 [1714267.001]
  • [Cites] Hepatology. 1991 Nov;14(5):802-5 [1657754.001]
  • [Cites] Ann Surg. 1993 Aug;218(2):145-51 [8393649.001]
  • [Cites] Hepatogastroenterology. 1993 Aug;40(4):328-32 [8406301.001]
  • [Cites] Semin Surg Oncol. 1993 Jul-Aug;9(4):298-304 [8210909.001]
  • [Cites] Gastroenterology. 1994 Mar;106(3):720-7 [8119543.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):28-34; discussion 34-5 [7817995.001]
  • [Cites] Arch Surg. 1995 Oct;130(10):1090-7 [7575122.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):297-302 [8604911.001]
  • [Cites] Br J Surg. 1996 Mar;83(3):330-3 [8665183.001]
  • [Cites] Am J Surg. 1996 Jul;172(1):29-34 [8686798.001]
  • [Cites] Br J Surg. 1996 Sep;83(9):1219-22 [8983610.001]
  • [Cites] Hepatology. 1998 Nov;28(5):1241-6 [9794907.001]
  • [CommentIn] Nat Clin Pract Gastroenterol Hepatol. 2006 Jan;3(1):18-9 [16397606.001]
  • [CommentIn] Nat Clin Pract Gastroenterol Hepatol. 2006 Jan;3(1):20-1 [16397607.001]
  • (PMID = 16041216.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1357731
  •  go-up   go-down


55. Xiao JD, Shen SR: [Expression and significance of NGX6 gene in human hepatocellular carcinoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Oct;33(10):937-41
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of NGX6 gene in human hepatocellular carcinoma].
  • OBJECTIVE: To examine the expression of NGX6 gene and to investigate its association with the clinico-pathological characteristics in hepatocellular carcinoma(HCC).
  • METHODS: Samples from 45 patients were divided into the hepatocellular carcinoma tissue group and the matched paracancerous tissue group.
  • Reverse transcription polymerase chain reaction(RT-PCR) was used to detect the expression of NGX6 gene in the hepatocellular carcinoma and the surrounding normal tissue specimens.
  • RESULTS: The positive rates of NGX6 in the hepatocellular carcinoma and the matched paracancerous tissues were 35.5%(16/45)and 77.8%(35/45), and the ratios of NGX6/G3PDH mRNA were 0.245+/-0.060 and 0.352+/-0.113.There was significant difference in the 2 groups (P<0.05).
  • The expression of NGX6 gene was related to TNM staging (chi2=6.106,P=0.042)and lymph node metastasis(chi2=5.237,P=0.022)in hepatocellular carcinoma.
  • CONCLUSION: There is positive expression of NGX6 in the hepatocellular carcinoma and the matched paracancerous tissues.
  • The low-expression or non-expression of NGX6 gene plays an important role in the gene transcription level in hepatocellular carcinoma.The expression of NGX6 gene is related with TNM staging and lymph node metastasis in hepatocellular carcinoma.
  • Expression of NGX6 might be used as an early indicator of the occurrence and development of hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Liver Neoplasms / genetics. Membrane Proteins / biosynthesis. Tumor Suppressor Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Female. Humans. Male. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19001737.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / TMEM8B protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


56. Liu SY, Wu F, Tao YM, Yang LY: [Increased expression of Abi1 in hepatocellular carcinoma and its correlation with poor prognosis of hepatocellular carcinoma]. Zhonghua Wai Ke Za Zhi; 2009 Nov 15;47(22):1732-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Increased expression of Abi1 in hepatocellular carcinoma and its correlation with poor prognosis of hepatocellular carcinoma].
  • OBJECTIVE: To investigate the expression of Abi1 in hepatocellular carcinoma (HCC) and the correlation between its expression level and clinical pathological characteristics as well as prognosis of HCC.
  • METHODS: Abi1 expression was determined at both mRNA and protein levels in 40 HCC tissues and their corresponding para carcinomatous liver tissues by RT-PCR and immunohistochemistry.
  • RESULTS: The expression level of Abi1 mRNA in HCC tissues were significantly higher than those in corresponding para carcinomatous liver tissue (P < 0.05), and the expression level of Abi1 mRNA in nodular HCC tissues were also significantly higher than those in solitary large HCC tissues.
  • CONCLUSIONS: Expression level of Abi1 is up-regulated in HCC tissues compared with corresponding para carcinomatous liver tissue and the expression level of Abi1 is significantly correlated with the number of tumor, capsular formation, venous invasion, Edmondson-Steiner grade and prognosis of HCC.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Carcinoma, Hepatocellular / metabolism. Cytoskeletal Proteins / metabolism. Liver Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis. RNA, Messenger / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137729.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ABI1 protein, human; 0 / Adaptor Proteins, Signal Transducing; 0 / Cytoskeletal Proteins; 0 / RNA, Messenger
  •  go-up   go-down


57. Yang JD, Roberts LR: Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am; 2010 Dec;24(4):899-919, viii
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology and management of hepatocellular carcinoma.
  • Hepatocellular carcinoma (HCC) is a major world health problem because of the high incidence and case fatality rate.
  • Most HCCs develop in patients with underlying chronic liver disease.
  • Chronic viral hepatitis B and C are the major causes of liver cirrhosis and HCC.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Hepatology. 2004 Mar;39(3):804-10 [14999700.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):796-802 [15305412.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1521-31 [15470215.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S194-205 [15508085.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16 [15508102.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S56-61 [15508104.001]
  • [Cites] Cancer. 1988 May 15;61(10):1942-56 [2834034.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):2051-5 [2844388.001]
  • [Cites] Hepatology. 1991 Mar;13(3):398-406 [1847891.001]
  • [Cites] World J Surg. 1991 Mar-Apr;15(2):270-85 [1851588.001]
  • [Cites] N Engl J Med. 1991 Sep 5;325(10):675-80 [1651452.001]
  • [Cites] Surgery. 1991 Oct;110(4):726-34; discussion 734-5 [1656538.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):925-9 [1310435.001]
  • [Cites] N Engl J Med. 1992 Aug 6;327(6):369-73 [1320736.001]
  • [Cites] Hepatology. 1992 Aug;16(2):353-7 [1322349.001]
  • [Cites] Cancer Res. 1993 Feb 15;53(4):790-4 [8381328.001]
  • [Cites] J Infect Dis. 1993 Mar;167(3):572-6 [8382718.001]
  • [Cites] N Engl J Med. 1993 Jun 24;328(25):1797-801 [7684822.001]
  • [Cites] Hepatology. 1993 Dec;18(6):1326-33 [8244256.001]
  • [Cites] N Engl J Med. 1994 Mar 17;330(11):744-50 [8107740.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):1000-5 [8143967.001]
  • [Cites] Gastroenterology. 1994 Jun;106(6):1618-24 [8194710.001]
  • [Cites] J Virol. 1995 Jun;69(6):3893-6 [7745741.001]
  • [Cites] Hepatology. 1995 Aug;22(2):432-8 [7543434.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Cancer. 1996 May 1;77(9):1792-6 [8646676.001]
  • [Cites] N Engl J Med. 1996 Jun 27;334(26):1685-90 [8637512.001]
  • [Cites] Gastroenterology. 1996 Oct;111(4):1018-22 [8831597.001]
  • [Cites] Abdom Imaging. 1996 Nov-Dec;21(6):488-94 [8875869.001]
  • [Cites] J Hepatol. 1996 Sep;25(3):334-8 [8895013.001]
  • [Cites] N Engl J Med. 1997 Jun 26;336(26):1855-9 [9197213.001]
  • [Cites] Acta Gastroenterol Belg. 1998 Apr-Jun;61(2):189-91 [9658605.001]
  • [Cites] Hepatology. 1999 Mar;29(3):971-5 [10051505.001]
  • [Cites] Hepatology. 1999 Jun;29(6):1870-5 [10347132.001]
  • [Cites] Ann Intern Med. 1999 Aug 3;131(3):174-81 [10428733.001]
  • [Cites] N Engl J Med. 1999 Aug 19;341(8):556-62 [10451460.001]
  • [Cites] Semin Liver Dis. 1999;19(3):329-38 [10518312.001]
  • [Cites] Gastroenterology. 2004 Dec;127(6):1714-23 [15578509.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22 [15042359.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Oncogene. 2003 Jun 19;22(25):3911-6 [12813464.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] J Vasc Interv Radiol. 2007 Jul;18(7):856-61 [17609444.001]
  • [Cites] Science. 2007 Jul 6;317(5834):121-4 [17615358.001]
  • [Cites] Hepatology. 2008 Jan;47(1):82-9 [18008357.001]
  • [Cites] Antivir Ther. 2007;12(8):1295-303 [18240869.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):459-64 [18387499.001]
  • [Cites] AJR Am J Roentgenol. 2008 May;190(5):1341-8 [18430853.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):111-21 [18505690.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Hepatology. 2008 Sep;48(3):819-27 [18688876.001]
  • [Cites] Gastroenterology. 2008 Sep;135(3):947-55, 955.e1-5 [18639551.001]
  • [Cites] Ann Surg. 2008 Oct;248(4):617-25 [18936575.001]
  • [Cites] Gut. 2008 Nov;57(11):1592-6 [18669577.001]
  • [Cites] N Engl J Med. 2008 Dec 4;359(23):2429-41 [19052125.001]
  • [Cites] Ann Surg. 2009 Jan;249(1):20-5 [19106671.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):138-48 [18848939.001]
  • [Cites] Cancer. 2009 Feb 1;115(3):616-23 [19117042.001]
  • [Cites] Dig Dis Sci. 2009 Mar;54(3):661-9 [18649138.001]
  • [Cites] Eur Radiol. 2009 Apr;19(4):951-9 [18989675.001]
  • [Cites] Hepatology. 2005 Apr;41(4):707-16 [15795889.001]
  • [Cites] J Hepatol. 2005 May;42(5):760-77 [15826727.001]
  • [Cites] Semin Liver Dis. 2005;25(2):212-25 [15918149.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] Liver Transpl. 2005 Dec;11(12):1505-14 [16315294.001]
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1207-15; discussion 1215 [16332475.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):65-73 [16391218.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):321-8 [16495695.001]
  • [Cites] Hepatology. 2006 May;43(5):891-902 [16628664.001]
  • [Cites] Gastroenterology. 2006 Aug;131(2):461-9 [16890600.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):792-800 [16904840.001]
  • [Cites] Ann Surg. 2007 Jan;245(1):36-43 [17197963.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jan;5(1):118-23 [17008133.001]
  • [Cites] Ann Intern Med. 2007 May 1;146(9):649-56 [17470833.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):1016-27; discussion 1027-8 [17481532.001]
  • [Cites] Gastroenterology. 2007 May;132(5):1740-5 [17484871.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1485-91 [19224838.001]
  • [Cites] Gastroenterology. 2009 May;136(5):1601-8 [19208359.001]
  • [Cites] Hepatology. 2009 May;49(5):1563-70 [19399911.001]
  • [Cites] Gastroenterology. 2009 Jul;137(1):110-8 [19362088.001]
  • [Cites] Radiology. 2009 Sep;252(3):905-13 [19567647.001]
  • [Cites] J Natl Cancer Inst. 2009 Oct 7;101(19):1348-55 [19759364.001]
  • [Cites] Nat Rev Gastroenterol Hepatol. 2010 Aug;7(8):448-58 [20628345.001]
  • [Cites] Hepatology. 1999 Dec;30(6):1434-40 [10573522.001]
  • [Cites] Curr Top Microbiol Immunol. 2000;242:117-34 [10592658.001]
  • [Cites] Hepatogastroenterology. 1999 Nov-Dec;46(30):3216-22 [10626189.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jan 19;267(2):581-7 [10631105.001]
  • [Cites] J Virol. 2000 Mar;74(6):2840-6 [10684300.001]
  • [Cites] Hepatology. 2000 Mar;31(3):777-82 [10706572.001]
  • [Cites] Hepatology. 2000 Apr;31(4):840-5 [10733537.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1117-32 [10751335.001]
  • [Cites] Gut. 2001 Feb;48(2):251-9 [11156649.001]
  • [Cites] Lancet. 2001 Jan 20;357(9251):196-7 [11213099.001]
  • [Cites] J Hepatol. 2001 Feb;34(2):306-13 [11281561.001]
  • [Cites] Am J Gastroenterol. 2001 Apr;96(4):1160-3 [11316164.001]
  • [Cites] Aliment Pharmacol Ther. 2001 May;15(5):689-98 [11328263.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1394-403 [11391528.001]
  • [Cites] J Hepatol. 2001 Apr;34(4):570-5 [11394657.001]
  • [Cites] J Hepatol. 2001 Apr;34(4):593-602 [11394661.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 1;93(15):1171-3 [11481390.001]
  • [Cites] Hepatology. 2001 Sep;34(3):529-34 [11526539.001]
  • [Cites] J Hepatol. 2001 Aug;35(2):254-8 [11580148.001]
  • [Cites] Ann Intern Med. 2001 Nov 6;135(9):796-800 [11694104.001]
  • [Cites] Science. 2001 Dec 14;294(5550):2376-8 [11743208.001]
  • [Cites] Hepatology. 2002 Jan;35(1):217-23 [11786979.001]
  • [Cites] Am J Epidemiol. 2002 Feb 15;155(4):323-31 [11836196.001]
  • [Cites] Oncology. 2002;62 Suppl 1:5-7 [11868786.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1747-52 [11920537.001]
  • [Cites] Am J Gastroenterol. 2002 Mar;97(3):734-44 [11922571.001]
  • [Cites] N Engl J Med. 2002 Apr 4;346(14):1074-82 [11932476.001]
  • [Cites] Hepatology. 2002 May;35(5):1164-71 [11981766.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1734-9 [12049862.001]
  • [Cites] N Engl J Med. 2002 Jul 18;347(3):168-74 [12124405.001]
  • [Cites] Liver Transpl. 2002 Oct;8(10):873-83 [12360427.001]
  • [Cites] Hepatology. 2002 Nov;36(5):1206-13 [12395331.001]
  • [Cites] J Vasc Interv Radiol. 2002 Dec;13(12):1225-32 [12471186.001]
  • [Cites] J Hepatol. 2003 Feb;38(2):200-7 [12547409.001]
  • [Cites] Am J Epidemiol. 2003 Apr 15;157(8):674-82 [12697571.001]
  • [Cites] Oncogene. 2003 Jun 12;22(24):3813-20 [12802289.001]
  • [Cites] Liver Transpl. 2003 Jul;9(7):672-81 [12827551.001]
  • [Cites] Radiology. 2003 Jul;228(1):235-40 [12759473.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):31745-55 [12799372.001]
  • [Cites] Hepatology. 2003 Oct;38(4):1034-42 [14512891.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1733-41 [14724826.001]
  • (PMID = 20937457.001).
  • [ISSN] 1557-9824
  • [Journal-full-title] Infectious disease clinics of North America
  • [ISO-abbreviation] Infect. Dis. Clin. North Am.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100882; United States / NCI NIH HHS / CA / R56 CA100882; United States / NCI NIH HHS / CA / CA100882
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS550985; NLM/ PMC3949429
  •  go-up   go-down


58. Chen XP, Qiu FZ, Wu ZD, Zhang BX: Hepatectomy for huge hepatocellular carcinoma in 634 cases. World J Gastroenterol; 2006 Aug 7;12(29):4652-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatectomy for huge hepatocellular carcinoma in 634 cases.
  • AIM: To clarify the safety and feasibility of hepatectomy for huge hepatocellular carcinoma (HCC).
  • The majority of the liver resection were major resections, and combined resection of the adjacent organs or structures was common (17.2%).
  • The liver resection was combined with portal vein thrombectomy in 139 patients (21.9%).
  • The main causes of postoperative deaths were liver failure (n = 9), postoperative bleeding (n = 4) and septic complication (n = 1).
  • The 3-, 5- and 10-year survival rates after liver resection were 35.1%, 18.2% and 3.5%, respectively.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Incidence. Liver / pathology. Liver / surgery. Male. Middle Aged. Postoperative Complications / epidemiology. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1992 Oct;216(4):493-504; discussion 504-5 [1417198.001]
  • [Cites] Cancer. 1990 Nov 15;66(10):2174-9 [2171748.001]
  • [Cites] Am J Surg. 1994 Apr;167(4):399-403 [8179084.001]
  • [Cites] World J Surg. 1995 Mar-Apr;19(2):252-63 [7754632.001]
  • [Cites] Cancer. 1996 May 15;77(10):2022-31 [8640665.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):364-8 [10228823.001]
  • [Cites] Hepatology. 1991 Nov;14(5):802-5 [1657754.001]
  • [Cites] J R Coll Surg Edinb. 2002 Feb;47(1):389-99 [11874260.001]
  • [Cites] Am J Surg. 1969 Jan;117(1):78-84 [5782751.001]
  • [Cites] Gut. 1971 Nov;12(11):922-8 [5132225.001]
  • [Cites] Cancer. 1984 Oct 15;54(8):1747-55 [6089997.001]
  • [Cites] Ann Surg. 1987 Jan;205(1):33-40 [3026259.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;23 Suppl:S129-32 [2538260.001]
  • [Cites] Jpn J Surg. 1989 Jan;19(1):98-129 [2659865.001]
  • [Cites] Cancer. 1989 Jul 15;64(2):536-41 [2544255.001]
  • [Cites] World J Surg. 1989 Sep-Oct;13(5):644-8 [2554598.001]
  • [Cites] Gastroenterology. 1990 Mar;98(3):733-8 [2153601.001]
  • [Cites] Cancer. 1990 Mar 1;65(5):1104-10 [2154320.001]
  • [Cites] Surgery. 1993 Jun;113(6):612-8 [8389492.001]
  • (PMID = 16937434.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087828
  •  go-up   go-down


59. White CD, Khurana H, Gnatenko DV, Li Z, Odze RD, Sacks DB, Schmidt VA: IQGAP1 and IQGAP2 are reciprocally altered in hepatocellular carcinoma. BMC Gastroenterol; 2010;10:125
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IQGAP1 and IQGAP2 are reciprocally altered in hepatocellular carcinoma.
  • We recently reported that IQGAP2 deficiency leads to the development of hepatocellular carcinoma (HCC) in mice.
  • RESULTS: IQGAP1 and IQGAP2 expression was reciprocally altered in 6/6 liver cancer cell lines.
  • Immunostaining of IQGAP1 and IQGAP2 may aid in the diagnosis of HCC, and their pharmacologic modulation may represent a novel therapeutic strategy for the treatment of liver cancer.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Liver Neoplasms / genetics. ras GTPase-Activating Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Blotting, Western. Female. Genetic Predisposition to Disease. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Apr 15;101(8):3021-8 [12515716.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1101-7 [12937151.001]
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):41237-45 [12900413.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17329-37 [14970219.001]
  • [Cites] Adv Anat Pathol. 2004 Sep;11(5):239-49 [15322490.001]
  • [Cites] Genome Res. 1996 Oct;6(10):986-94 [8908518.001]
  • [Cites] Nat Struct Biol. 1997 Mar;4(3):175-9 [9164454.001]
  • [Cites] Science. 1998 Aug 7;281(5378):832-5 [9694656.001]
  • [Cites] J Biol Chem. 1999 Jan 1;274(1):464-70 [9867866.001]
  • [Cites] Trends Biochem Sci. 1999 Feb;24(2):73-6 [10098402.001]
  • [Cites] J Biol Chem. 1999 Sep 10;274(37):26044-50 [10473551.001]
  • [Cites] Dev Cell. 2004 Dec;7(6):871-83 [15572129.001]
  • [Cites] J Cell Sci. 2005 May 15;118(Pt 10):2085-92 [15890984.001]
  • [Cites] Thromb Haemost. 2005 Aug;94(2):412-21 [16113833.001]
  • [Cites] Mol Cell Biol. 2005 Sep;25(18):7940-52 [16135787.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):561-8 [16449996.001]
  • [Cites] Trends Cell Biol. 2006 May;16(5):242-9 [16595175.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):674-87 [16929323.001]
  • [Cites] BMC Bioinformatics. 2006;7:431 [17022803.001]
  • [Cites] Clin Chem. 2007 Jan;53(1):17-23 [17095538.001]
  • [Cites] J Cell Sci. 2007 Feb 15;120(Pt 4):567-77 [17244649.001]
  • [Cites] Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R50-9 [17613547.001]
  • [Cites] Int J Cancer. 2008 Mar 1;122(5):1040-6 [17957782.001]
  • [Cites] J Biol Chem. 2008 Jan 11;283(2):1008-17 [17981797.001]
  • [Cites] Mol Cell Biol. 2008 Mar;28(5):1489-502 [18180285.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2391-9 [18381447.001]
  • [Cites] Am J Clin Pathol. 2008 Jun;129(6):899-906 [18480006.001]
  • [Cites] J Cell Biol. 2008 Jun 16;181(6):985-98 [18541705.001]
  • [Cites] Arch Pathol Lab Med. 2008 Nov;132(11):1723-8 [18976006.001]
  • [Cites] J Gastroenterol. 2009;44 Suppl 19:136-41 [19148808.001]
  • [Cites] J Cell Sci. 2009 Jun 15;122(Pt 12):2024-33 [19454477.001]
  • [Cites] FEBS Lett. 2009 Jun 18;583(12):1817-24 [19433088.001]
  • [Cites] Eur J Hum Genet. 2010 Jan;18(1):81-7 [19639020.001]
  • [Cites] Carcinogenesis. 2010 Mar;31(3):504-11 [20015863.001]
  • [Cites] Mol Genet Genomics. 2010 Apr;283(4):341-9 [20165882.001]
  • [Cites] Exp Mol Pathol. 2010 Apr;88(2):287-92 [20079733.001]
  • [Cites] Carcinogenesis. 2010 May;31(5):766-76 [19843643.001]
  • [Cites] Oncogene. 2008 Sep 18;27(42):5578-89 [18504433.001]
  • [Cites] J Biol Chem. 1999 Dec 31;274(53):37885-92 [10608854.001]
  • [Cites] Trends Genet. 2000 Apr;16(4):168-74 [10729832.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):7453-65 [11734550.001]
  • [Cites] Hepatology. 2002 May;35(5):1134-43 [11981763.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):339-46 [12149612.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):978-88 [12170084.001]
  • [Cites] Mod Pathol. 2002 Dec;15(12):1279-87 [12481008.001]
  • (PMID = 20977743.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / IQ motif containing GTPase activating protein 1; 0 / IQGAP2 protein, human; 0 / ras GTPase-Activating Proteins
  • [Other-IDs] NLM/ PMC2988069
  •  go-up   go-down


60. Kwong SL, Stewart SL, Aoki CA, Chen MS Jr: Disparities in hepatocellular carcinoma survival among Californians of Asian ancestry, 1988 to 2007. Cancer Epidemiol Biomarkers Prev; 2010 Nov;19(11):2747-57
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disparities in hepatocellular carcinoma survival among Californians of Asian ancestry, 1988 to 2007.
  • BACKGROUND: Hepatocellular carcinoma (HCC) represents a significant health disparity affecting Asian Americans, a population comprised of distinct ethnic groups.
  • RESULTS: Compared with the average of all ethnic groups, cause-specific mortality was significantly higher among Laotian/Hmong [hazard ratio, 2.08; 95% confidence interval (95% CI), 1.78-2.44] and Cambodian patients (hazard ratio, 1.26; 95% CI, 1.06-1.51), groups with higher proportions of their populations at low levels of socioeconomic status; in addition, Laotian/Hmong patients disproportionately presented at later stages of disease, with only 3% receiving local surgical treatment, resection, or liver transplantation.
  • [MeSH-major] Carcinoma, Hepatocellular / ethnology. Carcinoma, Hepatocellular / mortality. Healthcare Disparities / ethnology. Liver Neoplasms / ethnology. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Asian Americans / ethnology. California / epidemiology. California / ethnology. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Registries. SEER Program

  • MedlinePlus Health Information. consumer health - Health Disparities.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jan;4(1):104-10; quiz 4-5 [16431312.001]
  • [Cites] Cancer. 2005 Dec 15;104(12 Suppl):2895-902 [16270313.001]
  • [Cites] Cancer Causes Control. 2006 Aug;17(6):771-81 [16783605.001]
  • [Cites] Hepatology. 2007 Feb;45(2):507-39 [17256718.001]
  • [Cites] Cancer. 2007 May 15;109(10):2100-8 [17385214.001]
  • [Cites] World J Surg. 2007 Jun;31(6):1243-8 [17440771.001]
  • [Cites] Am J Epidemiol. 2007 Jul 1;166(1):97-103 [17463050.001]
  • [Cites] CA Cancer J Clin. 2007 Jul-Aug;57(4):190-205 [17626117.001]
  • [Cites] J Clin Gastroenterol. 2007 Sep;41(8):777-82 [17700427.001]
  • [Cites] Am J Epidemiol. 2007 Nov 1;166(9):1105-6; author reply 1106-7 [17881381.001]
  • [Cites] Hepatology. 2007 Oct;46(4):1034-40 [17654490.001]
  • [Cites] J Cancer Educ. 2007 Winter;22(4):266-72 [18067441.001]
  • [Cites] Am J Gastroenterol. 2008 Jan;103(1):120-7 [18005365.001]
  • [Cites] Cancer Causes Control. 2008 Apr;19(3):227-56 [18066673.001]
  • [Cites] Am J Surg. 2008 Jun;195(6):829-36 [18436176.001]
  • [Cites] MMWR Recomm Rep. 2008 Sep 19;57(RR-8):1-20 [18802412.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2173-9 [18792066.001]
  • [Cites] Clin Liver Dis. 2009 Feb;13(1):63-6 [19150310.001]
  • [Cites] BMC Cancer. 2009;9:46 [19193234.001]
  • [Cites] J Gastroenterol Hepatol. 2009 Mar;24(3):346-53 [19220670.001]
  • [Cites] J Epidemiol Community Health. 2009 Oct;63(10):856-61 [19542076.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2701-8 [19789367.001]
  • [Cites] Prev Med. 2010 Jan-Feb;50(1-2):63-7 [19716379.001]
  • [Cites] Prev Med. 2010 Jan-Feb;50(1-2):68-73 [19883680.001]
  • [Cites] Cancer. 2010 Feb 1;116(3):544-73 [19998273.001]
  • [Cites] J Clin Gastroenterol. 2010 Mar;44(3):e63-70 [19745756.001]
  • [Cites] Cancer. 2010 Mar 1;116(5):1367-77 [20101732.001]
  • [Cites] J Gen Intern Med. 2010 Jul;25(7):694-700 [20306150.001]
  • [Cites] J Health Care Poor Underserved. 2010 Aug;21(3):839-50 [20693730.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):703-11 [11562110.001]
  • [Cites] Oncology. 2002;62 Suppl 1:8-17 [11868791.001]
  • [Cites] Rev Gastroenterol Disord. 2003 Summer;3(3):125-34 [14502116.001]
  • [Cites] Cancer Causes Control. 2004 Apr;15(3):243-53 [15090719.001]
  • [Cites] Am J Prev Med. 2004 Aug;27(2):132-8 [15261900.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1229-35 [15305188.001]
  • [Cites] Cancer Causes Control. 1997 Sep;8(5):705-12 [9328192.001]
  • [Cites] Ethn Dis. 1998;8(2):218-27 [9681287.001]
  • [Cites] Cancer Causes Control. 1998 Aug;9(4):369-80 [9794168.001]
  • [Cites] Semin Liver Dis. 1999;19(3):329-38 [10518312.001]
  • [Cites] Gut. 2005 Mar;54(3):411-8 [15710992.001]
  • [Cites] Hepatology. 2005 Apr;41(4):707-16 [15795889.001]
  • [Cites] Oral Oncol. 2005 Jul;41(6):596-601 [15975522.001]
  • [Cites] Cancer. 2005 Dec 15;104(12 Suppl):2975-81 [16247792.001]
  • [Cites] Cancer. 2005 Dec 15;104(12 Suppl):2969-74 [16247793.001]
  • [Cites] Cancer Causes Control. 2006 Apr;17(3):267-72 [16489534.001]
  • (PMID = 20823106.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / PHS HHS / / U55/CCR921930-02; United States / NCI NIH HHS / CA / P30 CA093373; United States / NCI NIH HHS / CA / P01 CA109091-01A1; United States / NCI NIH HHS / CA / P01 CA109091; United States / NCI NIH HHS / PC / N02 PC015105; United States / NCI NIH HHS / CA / U01 CA114640; United States / NCI NIH HHS / CA / P01 CA109091-01A1S
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS234687; NLM/ PMC3016919
  •  go-up   go-down


61. Aishima S, Nishihara Y, Kuroda Y, Taguchi K, Iguchi T, Taketomi A, Maehara Y, Tsuneyoshi M: Histologic characteristics and prognostic significance in small hepatocellular carcinoma with biliary differentiation: subdivision and comparison with ordinary hepatocellular carcinoma. Am J Surg Pathol; 2007 May;31(5):783-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic characteristics and prognostic significance in small hepatocellular carcinoma with biliary differentiation: subdivision and comparison with ordinary hepatocellular carcinoma.
  • The morphologic characteristics and biologic behavior of small liver cancers with hepatic and biliary differentiation, and their histogenesis, remain unclear.
  • In this study, 35 cases of hepatocellular carcinoma (HCC) smaller than 3 cm in diameter with biliary differentiation were divided into 3 groups, group 1 [cytokeratin (CK) 19-negative/mucin-negative], group 2 (CK 19-positive/mucin-negative), and group 3 (CK 19-positive/mucin-positive).
  • (1) cancer cells with intermediate morphology, (2) prominent inflammatory cell infiltrate, (3) desmoplastic stroma; neural cell adhesion molecule and c-kit expression were noted in 25.7%(9/35) and 8.6%(3/35), respectively.
  • The combination of intermediate cancer cells, inflammatory cell infiltrate, and desmoplastic stroma is likely to be related to the biliary differentiation of HCC.
  • [MeSH-major] Bile Ducts / pathology. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic. Disease-Free Survival. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Hepatectomy. Humans. Keratin-19 / metabolism. Male. Middle Aged. Mucins / metabolism. Neoplasm Recurrence, Local. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460464.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / Mucins
  •  go-up   go-down


62. Romero Marrero C, Ortiz AP, Pérez CM, Pérez J, Torres EA: Survival of hepatocellular carcinoma in Puerto Rico. P R Health Sci J; 2009 Jun;28(2):105-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of hepatocellular carcinoma in Puerto Rico.
  • BACKGROUND: Blacks and Hispanics in the United States (US) have the lowest survival rates of hepatocellular carcinoma (HCC), mainly associated to the presence of advanced disease at diagnosis when intervention is least beneficial.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Age Factors. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Hepatectomy. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Proportional Hazards Models. Puerto Rico / epidemiology. Registries. Risk. Statistics, Nonparametric. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S248-60 [15508091.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34 [15508094.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22 [15042359.001]
  • [Cites] Radiology. 2005 Mar;234(3):961-7 [15665226.001]
  • [Cites] Clin Liver Dis. 2005 May;9(2):235-51, vi [15831271.001]
  • [Cites] Int J Epidemiol. 2005 Jun;34(3):593-9 [15802378.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jan;4(1):104-10; quiz 4-5 [16431312.001]
  • [Cites] Gastroenterology. 2008 May;134(6):1752-63 [18471552.001]
  • [Cites] Arch Intern Med. 2007 Oct 8;167(18):1983-9 [17923599.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2535-42 [14638360.001]
  • [Cites] Ann Intern Med. 2003 Nov 18;139(10):817-23 [14623619.001]
  • [Cites] Clin Liver Dis. 2001 Feb;5(1):87-107, vi [11218921.001]
  • [Cites] Hepatology. 1999 Dec;30(6):1434-40 [10573522.001]
  • (PMID = 19530551.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / R25 RR017589-08; United States / NCRR NIH HHS / RR / R25 RR17589; United States / NCI NIH HHS / CA / U54 CA096297; United States / NCRR NIH HHS / RR / R25 RR017589; United States / NCCDPHP CDC HHS / DP / U58 DP000782; United States / NCRR NIH HHS / RR / G12 RR003051; United States / NCI NIH HHS / CA / U54 CA096297-07; United States / NCRR NIH HHS / RR / G12RR03051; United States / NCRR NIH HHS / RR / G12 RR003051-24; United States / NIMHD NIH HHS / MD / G12 MD007600; United States / NCCDPHP CDC HHS / DP / U58DP000782-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Puerto Rico
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS209148; NLM/ PMC3861879
  •  go-up   go-down


63. Nakamura S, Nouso K, Noguchi Y, Higashi T, Ono T, Jungbluth A, Chen YT, Old LJ, Nakayama E, Shiratori Y: Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. J Gastroenterol Hepatol; 2006 Aug;21(8):1281-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma.
  • BACKGROUND AND AIM: The present study was designed to investigate the expression of and humoral response against NY-ESO-1 in patients with hepatocellular carcinoma and to analyze the relationship between expression of NY-ESO-1 mRNA and clinicopathological features.
  • METHODS: NY-ESO-1 mRNA and protein expression in surgically resected hepatocellular carcinoma specimens, adjacent non-cancerous liver and non-tumor bearing liver were examined by reverse transcription-polymerase chain reaction and immunohistochemical staining using a monoclonal antibody against NY-ESO-1 (ES121), respectively.
  • RESULTS: NY-ESO-1 mRNA was detected in 18 of 41 (43.9%) hepatocellular carcinomas.
  • No NY-ESO-1 mRNA was expressed in 41 paired non-cancerous specimens and 18 specimens histologically diagnosed as liver cirrhosis or chronic hepatitis.
  • Immunohistochemistry revealed heterogeneous expression of NY-ESO-1 protein in three of 18 NY-ESO-1 mRNA-positive hepatocellular carcinomas.
  • None of 23 NY-ESO-1 mRNA-negative hepatocellular carcinomas expressed NY-ESO-1 protein.
  • Antibody against NY-ESO-1 protein was detected in two of 92 patients with hepatocellular carcinoma.
  • CONCLUSIONS: The present study has demonstrated the expression of NY-ESO-1 mRNA in hepatocellular carcinoma and NY-ESO-1 antibody production in patients with advanced hepatocellular carcinoma.
  • Although the enhancement of NY-ESO-1 protein expression and the activation of immune response of the patients with hepatocellular carcinoma are necessary, NY-ESO-1 has the potential to be a good target molecule for immunotherapy against advanced hepatocellular carcinoma.
  • [MeSH-major] Antigens, Neoplasm / genetics. Carcinoma, Hepatocellular / genetics. Liver Neoplasms / genetics. Membrane Proteins / genetics
  • [MeSH-minor] Adult. Aged. DNA, Neoplasm / analysis. Female. Gene Expression. Humans. Immunohistochemistry. Liver / pathology. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16872310.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CTAG1B protein, human; 0 / DNA, Neoplasm; 0 / Membrane Proteins
  •  go-up   go-down


64. Nardello O, Farina GP, Cagetti M: [Obstructive jaundice caused by hepatocellular carcinoma]. Ann Ital Chir; 2005 Nov-Dec;76(6):535-41
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Obstructive jaundice caused by hepatocellular carcinoma].
  • The Authors take a hint from recent observation of two patients with hepatocellular carcinoma presenting with obstructive jaundice to analyse the litterature and their clinical cases.
  • They conclude that in the evolution of hepatocellular carcinoma can be found "early" or "late" jaundice.
  • The latest is hepatocellular and/or obstructive jaundice and it is harbinger of fatal prognosis because of a big hepatocelluar carcinoma that has invaded biliary tree and/or liver failure by concomitant cirrhosis.
  • This kind of jaundice has a good prognostic meaning because, together with imaging techniques, permits an early diagnosis of the hepatocellular carcinoma necessary for satisfactory palliation or occasional cure.
  • [MeSH-major] Carcinoma, Hepatocellular / complications. Jaundice, Obstructive / etiology. Liver Neoplasms / complications
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16821515.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 44
  •  go-up   go-down


65. Dyer Z, Peltekian K, van Zanten SV: Review article: the changing epidemiology of hepatocellular carcinoma in Canada. Aliment Pharmacol Ther; 2005 Jul 1;22(1):17-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review article: the changing epidemiology of hepatocellular carcinoma in Canada.
  • The aim of this study was to examine the incidence of and mortality caused by hepatocellular carcinoma over the last 20 years in Canada, including the associated risk factors hepatitis C, diabetes and obesity.
  • Databases from the Surveillance & Risk Assessment Division of Health Canada & Statistics Canada were analysed for trends in both age-adjusted incidence of and mortality due to hepatocellular carcinoma from 1984 to 2001.
  • The epidemiological impact of hepatitis C, diabetes and obesity on hepatocellular carcinoma was also assessed.
  • The incidence of hepatocellular carcinoma increased from 4.0 per 100,000 in 1984 to 5.5 in 2,000 for males, and from 1.6 per 100,000 in 1984 to 2.2 in 2,000 for females.
  • The prevalence of obesity and diabetes has increased in recent years and probably contributes to the increased incidence of hepatocellular carcinoma.
  • The incidence of hepatocellular carcinoma in Canada has increased in the past 20 years and is associated with a rise in the incidence of hepatitis C, obesity and diabetes.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Canada / epidemiology. Child. Child, Preschool. Diabetes Mellitus / epidemiology. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Obesity / epidemiology. Risk Factors. Sex Distribution

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15963075.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 29
  •  go-up   go-down


66. Masulović D, Milićević M, Marković Z, Saranović Dj, Sagić D, Maksimović R, Mijailović M: [Transcatether chemoembolization in the treatment of hepatocellular carcinoma]. Acta Chir Iugosl; 2009;56(4):139-42
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transcatether chemoembolization in the treatment of hepatocellular carcinoma].
  • The authors describe their own experience with chemoembolization as a palliation in the treatment of non resectable hepatocellular carcinoma.
  • MATERIAL/METHODS: During period of 64 months procedure was performed in 41 patients with non resectable hepatocellular carcinoma.
  • Liver cirrhosis was present in 36 patients, and abnormal levels of alpha-fetoprotein were found in 68% of cases.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Liver Neoplasms / therapy. Palliative Care
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20420010.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


67. Saliba T, Dorkhom S, O'Reilly EM, Ludwig E, Gansukh B, Abou-Alfa GK: Hepatocellular carcinoma in two patients with cardiac cirrhosis. Eur J Gastroenterol Hepatol; 2010 Jul;22(7):889-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in two patients with cardiac cirrhosis.
  • Hepatocellular carcinoma has been commonly associated with multiple etiologic factors including hepatitis B and C, alcoholic liver disease, and more rarely congenital metabolic liver diseases.
  • 'Cardiac cirrhosis' is the cirrhosis resulting from prolonged passive liver venous congestion secondary to right-sided congestive heart failure; hepatocellular carcinoma is a rarely reported outcome.
  • In this study we present two female patients with congenital heart defects treated with the Fontan procedure who survived into their third decade, and developed hepatocellular carcinoma in the setting of cardiac cirrhosis.
  • As such patients live longer, however elevated pulmonary and right-sided heart pressures cause chronic passive liver congestion and eventual cardiac cirrhosis.
  • The two patients in this study had no risk factors for hepatocellular carcinoma other than cardiac cirrhosis secondary to their prolonged survival after their Fontan procedure.
  • In conclusion, we suggest that cardiac cirrhosis may be a risk factor for developing hepatocellular carcinoma and recommend close follow-up and hepatocellular carcinoma screening for patients with known right heart failure and passive hepatic congestion.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / etiology. Fontan Procedure / adverse effects. Heart Defects, Congenital / surgery. Liver Neoplasms / diagnosis. Liver Neoplasms / etiology. Myocardium / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Female. Fibrosis. Heart Failure / diagnosis. Heart Failure / etiology. Humans

  • MedlinePlus Health Information. consumer health - Congenital Heart Defects.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19550346.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


68. Zhong XG, He S, Yin W, Deng JY, Chen B: [Tropism of adult liver stem cells toward hepatocellular carcinoma cells in vitro]. Zhonghua Gan Zang Bing Za Zhi; 2005 Sep;13(9):644-7
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tropism of adult liver stem cells toward hepatocellular carcinoma cells in vitro].
  • OBJECTIVE: To explore the biological behavior of adult liver stem cells in a co-cultured system of them with hepatocellular carcinoma (HCC) cells without direct contact between the two kinds of cells.
  • METHODS: WB-F344, a kind of rat adult liver stem cell, and rat embryonic fibroblasts (REF) from a primary culture were engineered to express enhanced green fluorescent protein (EGFP) by recombinant adenoviral-mediated methods.
  • After the HCC cells grew to 40%-60% confluence in the culture dish with a 10-mm cell-free area, a similar number of WB-EGFP and REF-EGFP were placed in the blank areas respectively.
  • Their appearance was found not only when WB-EGFP cells were seeded into the cell-free area at the center of the dish, but also when seeded into the blank area at the extreme edge of the plate.
  • CONCLUSIONS: The results mean that adult liver stem cells have a biological behavior of selective tropism toward HCC cells in vitro, and suggest a possibility of using migratory liver stem cells as a delivery vehicle for gene therapy for HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver / cytology. Liver Neoplasms / pathology. Stem Cells / cytology

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174449.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


69. Batsis JA, Halfdanarson TR, Pitot H: Extra-hepatic hepatocellular carcinoma presenting as obstructive jaundice. Dig Liver Dis; 2006 Oct;38(10):768-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extra-hepatic hepatocellular carcinoma presenting as obstructive jaundice.
  • Hepatocellular carcinoma is a neoplasm with a uniformly poor prognosis.
  • Risk factors for its development include chronic hepatitis B or C infection, haemochromatosis and alpha-1-antitrypsin deficiency, but individuals with any type of chronic liver disease are predisposed.
  • We present a patient with notable atypical clinical features for hepatocellular carcinoma.
  • The patient had neither predisposing risk factors nor a primary liver lesion causing obstructive jaundice.
  • Hepatocellular carcinoma generally requires a surgical cure, but patients who are icteric often portend poorer prognoses.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Jaundice, Obstructive / etiology. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Humans. Lymphatic Diseases / etiology. Male

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243009.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


70. Kchaou-Ouakaa A, Belhadjbrik N, Elloumi H, Gargouri D, Kochlef A, Kilani A, Romani M, Kharrat J, Ghorbel A: [Surveillance for hepatocellular carcinoma: does it work?]. Tunis Med; 2007 Oct;85(10):866-70
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surveillance for hepatocellular carcinoma: does it work?].
  • BACKGROUND: The surveillance of cirrhotic patients for early detection of hepatocellular carcinoma is recommended but its efficacy is now discussed.
  • METHODS: it is a retrospective study that included 110 patients with cirrhosis in a screening program of hepatocellular carcinoma, based on the realization of abdominal ultrasound exam and the determination of alpha-fetoprotein amount every 6 months in 95 patients and every 3 months in 15 patients.
  • A hepatocellular carcinoma was diagnosed in 13 patients.
  • CONCLUSIONS: systematic screening for hepatocellular carcinoma offer a limited cost effectiveness ratio.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Liver Cirrhosis / complications. Liver Neoplasms / diagnosis. Mass Screening / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Early Diagnosis. Embolization, Therapeutic. Female. Hepatectomy. Humans. Liver Failure / etiology. Male. Middle Aged. Population Surveillance. Prospective Studies. Retrospective Studies. Tomography, X-Ray Computed. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236810.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


71. Tischoff I, Tannapfel A: [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy]. Zentralbl Chir; 2007 Aug;132(4):300-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy].
  • Primary liver cancer is one of the most common cancer worldwide.
  • Beside hepatocellular carcinoma (HCC), accounting for more than 80%, cholangiocarcinoma (CC) is the second most frequent primary malignant epithelial liver tumor.
  • Combined hepatocellular-cholangiocarcinoma (HCC/CC) is a rare form of liver cancer with a frequency of 1%.
  • Both, hepatocellular carcinoma and cholangiocarcinoma, show a wide geographical variation with low-incidence areas in North America and Europe and high incidence areas in Africa and Asia.
  • Whereas hepatocellular carcinomas develop by malignant transformation of hepatocytes, cholangiocarcinomas arise from the small intrahepatic bile duct epithelium.
  • The UICC-TNM classification of malignant liver tumors is applied for both tumor entities.
  • 70-80% of hepatocellular carcinoma occur in cirrhotic liver.
  • In high incidence areas, such as Asia and Africa, HCC is strongly associated with chronic viral hepatitis B and C and liver cirrhosis.
  • But several risk factors including hepatolithiasis, liver fluke infection, and anatomical abnormalities associated with inflammation of the biliary tract have been described.
  • [MeSH-major] Bile Duct Neoplasms. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular. Cholangiocarcinoma. Liver Neoplasms
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Incidence. Liver / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724632.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 33
  •  go-up   go-down


72. Liu XH, Pan MH, Lu ZF, Wu B, Rao Q, Zhou ZY, Zhou XJ: Expression of Wnt-5a and its clinicopathological significance in hepatocellular carcinoma. Dig Liver Dis; 2008 Jul;40(7):560-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Wnt-5a and its clinicopathological significance in hepatocellular carcinoma.
  • AIM: To investigate the clinical significance of Wnt-5a expression in hepatocellular carcinoma.
  • Wnt-5a, beta-catenin, E-cadherin and Ki-67 were examined immunohistochemically in 114 hepatocellular carcinoma cases.
  • RESULTS: Compared to normal tissue, Wnt-5a mRNA expression was clearly increased in hepatocellular carcinoma, chronic hepatitis and cirrhosis.
  • On immunohistochemistry, immunostaining of Wnt-5a showed a bell-shaped pattern: low to undetectable levels were present in normal tissue and in tumour samples, whereas strong immunostaining was seen in chronic hepatitis, cirrhosis and dysplastic liver cells.
  • Reduction or loss of Wnt-5a protein expression was found in 80.7% of hepatocellular carcinoma cases (n=92) and was significantly associated with higher tumour stage (p<0.001), serum AFP level (p=0.025), low membranous expression of E-cadherin (p<0.0001) and beta-catenin (p=0.036) and high Ki-67 labelling indices (LIs, p=0.001).
  • However, Wnt-5a protein expression is frequently lost in hepatocellular carcinoma; this supports the notion that this protein has a tumour suppressor function in hepatocellular carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / chemistry. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / chemistry. Liver Neoplasms / pathology. Proto-Oncogene Proteins / analysis. Wnt Proteins / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Cadherins / analysis. Child. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294932.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins; 0 / WNT5A protein, human; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


73. Yahagi N, Shimano H, Hasegawa K, Ohashi K, Matsuzaka T, Najima Y, Sekiya M, Tomita S, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Nagai R, Ishibashi S, Kadowaki T, Makuuchi M, Ohnishi S, Osuga J, Yamada N: Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer; 2005 Jun;41(9):1316-22
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma.
  • Hepatocellular carcinoma is a very common neoplastic disease in countries where hepatitis viruses B and/or C are prevalent.
  • Small hepatocellular carcinoma lesions detected by ultrasonography at an early stage are often hyperechoic because they are composed of well-differentiated cancer cells that are rich in triglyceride droplets.
  • We therefore examined the mRNA expression of lipogenic enzymes in human hepatocellular carcinoma samples from 10 patients who had undergone surgical resection.
  • All of the samples exhibited marked elevation of expression of mRNA for lipogenic enzymes, such as fatty acid synthase, acetyl-CoA carboxylase and ATP citrate lyase, compared with surrounding non-cancerous liver tissue.
  • Thus, lipogenic enzymes are markedly induced in hepatocellular carcinomas, and in some cases SREBP-1c is involved in this activation.
  • [MeSH-major] CCAAT-Enhancer-Binding Proteins / metabolism. Carcinoma, Hepatocellular / enzymology. Coenzymes / metabolism. DNA-Binding Proteins / metabolism. Enzymes / metabolism. Liver Neoplasms / enzymology. Transcription Factors / metabolism. Triglycerides / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Northern. Enzyme Activation. Female. Hepatocytes / enzymology. Humans. Immunohistochemistry. Male. Middle Aged. RNA, Messenger / metabolism. Sterol Regulatory Element Binding Protein 1

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15869874.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Proteins; 0 / Coenzymes; 0 / DNA-Binding Proteins; 0 / Enzymes; 0 / RNA, Messenger; 0 / SREBF1 protein, human; 0 / Sterol Regulatory Element Binding Protein 1; 0 / Transcription Factors; 0 / Triglycerides
  •  go-up   go-down


74. Li WH, Cheuk EC, Kowk PC, Cheung MT: Survival after transarterial embolization for spontaneous ruptured hepatocellular carcinoma. J Hepatobiliary Pancreat Surg; 2009;16(4):508-12
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after transarterial embolization for spontaneous ruptured hepatocellular carcinoma.
  • OBJECTIVES: To examine the survival of patients with spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization (TAE).
  • METHODS AND MATERIALS: Patients diagnosed with spontaneous ruptured hepatocellular carcinoma treated with TAE were retrospectively studied.
  • A total of 62 patients who had been diagnosed with spontaneous ruptured hepatocellular carcinoma were managed in our hospital during this period.
  • RESULTS: All 62 patients (who had been diagnosed with ruptured hepatocellular carcinoma and were managed in our hospital) patients were treated with TAE, with a success rate of 91% (57/62).
  • CONCLUSION: Transarterial embolization (TAE) can achieve good hemostasis, though low albumin level, which reflects poor liver reserve, may predict early mortality.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Embolization, Therapeutic. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hemostasis, Surgical. Hospital Mortality. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Portal Vein. Retrospective Studies. Rupture, Spontaneous. Venous Thrombosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19381430.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


75. Chen XP, Wu ZD, Huang ZY, Qiu FZ: Use of hepatectomy and splenectomy to treat hepatocellular carcinoma with cirrhotic hypersplenism. Br J Surg; 2005 Mar;92(3):334-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of hepatectomy and splenectomy to treat hepatocellular carcinoma with cirrhotic hypersplenism.
  • BACKGROUND: The aim of this study was to compare the outcome after simultaneous hepatectomy and splenectomy with that after hepatectomy alone for hepatocellular carcinoma with associated hypersplenism.
  • METHODS: Two hundred and four patients with hepatocellular carcinoma and cirrhotic hypersplenism were divided non-randomly into two groups.
  • White blood cell (WBC) and platelet counts, total serum bilirubin levels, immune function, incidence of complications and 5-year survival rates in the two groups were compared.
  • RESULTS: WBC and platelet counts, distribution of T cell subsets, and levels of bilirubin, interferon gamma and interleukin 2 were different between the two groups after operation.
  • CONCLUSION: Simultaneous hepatectomy and splenectomy was associated with improved 5-year tumour-free survival in patients with hepatocellular carcinoma and hypersplenism.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Hypersplenism / surgery. Liver Neoplasms / surgery. Splenectomy / methods
  • [MeSH-minor] Adult. Cytokines / blood. Disease-Free Survival. Female. Fibrosis / surgery. Humans. Leukocyte Count. Male. Platelet Count. Postoperative Care. Preoperative Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 British Journal of Surgery Society Ltd.
  • (PMID = 15672441.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


76. Lin YM, Chang JH, Yeh KT, Yang MY, Liu TC, Lin SF, Su WW, Chang JG: Disturbance of circadian gene expression in hepatocellular carcinoma. Mol Carcinog; 2008 Dec;47(12):925-33
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disturbance of circadian gene expression in hepatocellular carcinoma.
  • The aims of this study are to understand the expression of the circadian genes between hepatocellular carcinoma tissues and nontumor tissues, and to explore the possible mechanism(s) contributing to the difference.
  • We analyzed differential expression of the 9 circadian genes in 46 hepatocellular carcinoma and paired noncancerous tissues by real-time quantitative RT-PCR and immunohistochemical detection.
  • Our results showed that decreased expression levels of PER1, PER2, PER3, CRY2, and TIM in hepatocellular carcinomas were observed.
  • The down expression of more circadian genes may result in disturbance of cell cycle, and it is correlated with the tumor size.
  • Downregulation of circadian genes results in disturbance of circadian rhythm in hepatocellular carcinoma which may disrupt the control of the central pacemaker and benefit selective survival of cancerous cells and promote carcinogenesis.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Circadian Rhythm / genetics. Gene Expression Regulation, Neoplastic. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Cell Cycle Proteins / genetics. Cryptochromes. Female. Flavoproteins / genetics. Humans. Immunohistochemistry. Intracellular Signaling Peptides and Proteins / genetics. Male. Middle Aged. Nuclear Proteins / genetics. Period Circadian Proteins. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factors / genetics. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18444243.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRY2 protein, human; 0 / Cell Cycle Proteins; 0 / Cryptochromes; 0 / Flavoproteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Nuclear Proteins; 0 / PER1 protein, human; 0 / PER2 protein, human; 0 / PER3 protein, human; 0 / Period Circadian Proteins; 0 / TIMELESS protein, human; 0 / Transcription Factors
  •  go-up   go-down


77. Cabrera R, Nelson DR: Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther; 2010 Feb 15;31(4):461-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review article: the management of hepatocellular carcinoma.
  • BACKGROUND: Hepatocellular carcinoma is the leading cause of death in cirrhosis.
  • AIM: To review the current screening, diagnosis and management strategies involved in hepatocellular carcinoma.
  • RESULTS: Hepatocellular carcinoma is dramatically increasing in incidence that is mostly attributed to chronic hepatitis C and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and its clinical phenotype diabetes and obesity.
  • Cirrhosis is the major predisposing risk factor and its presence necessitates close surveillance for hepatocellular carcinoma with serial imaging studies.
  • Hepatocellular carcinoma can be diagnosed by its unique radiological behaviour of arterial enhancement and washout on delayed images.
  • The Barcelona Clinic Liver Cancer staging classification system is a clinically useful algorithm for the management of patients with hepatocellular carcinoma.
  • A multidisciplinary approach is critical to the successful management of hepatocellular carcinoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / diagnosis. Liver Neoplasms / therapy. Pyridines / therapeutic use
  • [MeSH-minor] Ablation Techniques. Adult. African Continental Ancestry Group. Asian Continental Ancestry Group. Biopsy. Chemoembolization, Therapeutic. Contrast Media. Drug Eruptions / prevention & control. Female. Health Care Costs. Hepatitis B, Chronic / complications. Hepatitis B, Chronic / epidemiology. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / epidemiology. Humans. Incidence. Liver Cirrhosis / complications. Liver Cirrhosis / mortality. Liver Transplantation. Male. Middle Aged. Neoplasm Staging / methods. Neovascularization, Pathologic / drug therapy. Niacinamide / analogs & derivatives. Phenylurea Compounds. Population Surveillance. Practice Guidelines as Topic. Quality of Life. Randomized Controlled Trials as Topic. Recurrence. Risk Factors. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. United States / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Aliment Pharmacol Ther. 2010 May;31(10):1153-4 [20518755.001]
  • (PMID = 19925500.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Contrast Media; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Number-of-references] 96
  •  go-up   go-down


78. Kang KF, Wang XW, Chen XW, Tan GM, Kang ZJ: [Expression of Beclin1 in primary hepatocellular carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jan;29(1):151-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of Beclin1 in primary hepatocellular carcinoma].
  • OBJECTIVE: To detect Beclin1 expression and explore its clinical significance in primary hepatocellular carcinoma (HCC).
  • METHODS: Beclin1 expressions in 10 normal hepatic tissues, 30 hepatitis liver, 30 cirrhotic liver and 50 HCC tissues were detected by immunohistochemical staining.
  • RESULTS: The positivity rates of Beclin1 expression in the HCC, cirrhotic liver, hepatitis liver and normal liver tissues were 78.00% (39/50), 26.67% (8/30), 53.33% (16/30), and 10.00% (1/10), respectively, showing significant differences between them (chi(2)=28.31, P<0.05).
  • Beclin1 expression was significantly higher in HCC tissues than in the cirrhotic, hepatitis and normal liver tissues (chi(2)=20.39, 5.31, and 14.41, respectively, P<0.05), and hepatitis tissues showed significantly higher Beclin1 expression than hepatic cirrhosis tissues and normal hepatic tissues (chi(2)=4.44 and 4.12, respectively, P<0.05).
  • CONCLUSION: The abnormal expression of Beclin1 is closely associated with the pathogenesis and development of primary hepatocellular carcinoma, and may play an important role in this process.
  • [MeSH-major] Apoptosis Regulatory Proteins / metabolism. Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Membrane Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19218137.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BECN1 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


79. Miyoshi A, Takahashi T, Otsuka T, Kohya N, Miyazaki K: Efficacy of major hepatectomy for large hepatocellular carcinoma. Hepatogastroenterology; 2009 May-Jun;56(91-92):768-72
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of major hepatectomy for large hepatocellular carcinoma.
  • BACKGROUND/AIMS: Large hepatocellular carcinomas (HCC) with diameter >10 cm reportedly displays poor prognosis.
  • METHODOLOGY: From January 1987 to December 2004, a total of 252 patients with primary HCC underwent hepatic resection in our institution.
  • Liver cirrhosis and early recurrence were significantly less frequent in the major hepatectomy group than in the minor hepatectomy group (p=0.026; p=0.005).
  • CONCLUSIONS: Major hepatectomy can improve prognosis while preserving liver function for patients with large HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / pathology. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621699.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


80. Xie HJ, Bae HJ, Noh JH, Eun JW, Kim JK, Jung KH, Ryu JC, Ahn YM, Kim SY, Lee SH, Yoo NJ, Lee JY, Park WS, Nam SW: Mutational analysis of JAK1 gene in human hepatocellular carcinoma. Neoplasma; 2009;56(2):136-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutational analysis of JAK1 gene in human hepatocellular carcinoma.
  • The <em>Janus kinase 1</em> (JAK1) gene encodes a cytoplasmic tyrosine kinase that is noncovalently associated with a variety of cytokine receptors and plays a nonredundant role in cell proliferation, survival, and differentiation.
  • Thus, to investigate whether genetic mutations of JAK1 gene are associated in hepatocellular carcinoma (HCC) progression, we analyzed genetic alterations of JAK1 gene in 84 human HCCs by single-strand conformational polymorphism (SSCP) and direct sequencing.
  • Taken together, we found one novel missense mutation of JAK1 gene in hepatocellular carcinomas with some polymorphisms.
  • Although the functional assessment of this novel mutant remains to be completed, JAK1 mutation may contribute to the tumor development in liver cancer.
  • KEYWORDS: JAK1 gene, hepatocellular carcinoma, mutation.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Janus Kinase 1 / genetics. Liver Neoplasms / genetics. Mutation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Polymorphism, Single Nucleotide. Signal Transduction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19239328.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] EC 2.7.010.2 / JAK1 protein, human; EC 2.7.10.2 / Janus Kinase 1
  •  go-up   go-down


81. Tretiakova MS, Shabani-Rad MT, Guggisberg K, Hart J, Anders RA, Gao ZH: Genomic and immunophenotypical differences between hepatocellular carcinoma with and without cirrhosis. Histopathology; 2010 May;56(6):683-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic and immunophenotypical differences between hepatocellular carcinoma with and without cirrhosis.
  • AIMS: To compare the expression of genes involved in p53, Wnt/beta-catenin, and retinoblastoma (Rb) 1 pathways between cirrhosis-associated hepatocellular carcinoma (HCC-C) and hepatocellular carcinoma arising in non-cirrhotic liver (HCC-NC).
  • Compared with their background non-neoplastic liver tissue, HCC-C showed a significantly higher rate of p53, beta-catenin (protein only) and cyclin D1 expression, whereas HCC-NC showed a significantly higher rate of p21(Waf1/cip1) and p27(Kip1) expression.
  • CONCLUSIONS: Alteration of the p53 pathway plays a more important role in the pathogenesis of HCC-C, whereas alterations in cell cycle regulators p21(waf1/cip1) and p27(Kip1) play a more important role in the pathogenesis of HCC-NC.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Cirrhosis / complications. Liver Neoplasms / metabolism
  • [MeSH-minor] Adult. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism


82. Peng BG, He Q, Shen SL, Xie XY, Liang LJ, Kuang M, Lü MD: [Combined hepatic resection and intraoperative thermal ablation for multifocal hepatocellular carcinoma]. Zhonghua Wai Ke Za Zhi; 2009 Dec 1;47(23):1767-70
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined hepatic resection and intraoperative thermal ablation for multifocal hepatocellular carcinoma].
  • OBJECTIVE: To investigate the safety and efficacy of hepatic resection combined with intraoperative ablation to treat multifocal hepatocellular carcinoma.
  • METHODS: Clinical data of patients diagnosed with multifocal hepatocellular carcinoma and treated with hepatic resection combined with intraoperative ablation from March 1998 to September 2007 were retrospectively reviewed.
  • Postoperative complication included wound infection (1 case), bile leakage (1 case), subphrenic and pleural effusion (1 case), ablation-associated liver abscess (1 case), all of which were treated with non-surgical methods.
  • CONCLUSION: Hepatectomy combined with intraoperative thermal ablation provides a treatment modality for patients with multifocal hepatocellular carcinoma and may improve the prognosis.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation. Hepatectomy. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193542.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


83. Lee NP, Leung KW, Cheung N, Lam BY, Xu MZ, Sham PC, Lau GK, Poon RT, Fan ST, Luk JM: Comparative proteomic analysis of mouse livers from embryo to adult reveals an association with progression of hepatocellular carcinoma. Proteomics; 2008 May;8(10):2136-49
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative proteomic analysis of mouse livers from embryo to adult reveals an association with progression of hepatocellular carcinoma.
  • To identify potential oncofetal biomarkers that distinguish hepatocellular carcinoma (HCC) from healthy liver tissues, we compared and analyzed the proteomic profiles of mouse livers at different developmental stages.
  • Fetal (E13.5, E16.5), newborn (NB), postnatal (3-week) and adult (3-month) livers were isolated and profiled by 2-D PAGE.
  • Unsupervised hierarchical tree analysis segregated the proteins into fetal, NB, and postnatal-adult clusters.
  • Fetal markers (hPCNA, hHSP7C, hHEM6) and postnatal-adult markers (hARGI1, hASSY, hBHMT, hFABPL) were selected for testing against a panel of seven human hepatocyte/HCC cell lines and 59 clinical specimens.
  • The fetal proteins were found to be overexpressed in the metastatic HCC cell lines and the tumor tissues, whereas the postnatal-adult proteins were expressed in non-tumor tissues and normal hepatocytes.
  • This "Ying-Yang" pattern, as orchestrated by distinct fetal and adult markers, is hypothesized to indicate the progressive change of the liver from a growing, less-differentiated organ into a functional metabolic center.
  • Thus, embryogenesis and tumorigenesis share certain oncofetal markers and adult "hepatic" phenotypes are lost in HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver / metabolism. Liver Neoplasms / metabolism. Proteins / analysis. Proteomics / methods
  • [MeSH-minor] Animals. Animals, Newborn. Cell Line, Tumor. Cluster Analysis. Electrophoresis, Gel, Two-Dimensional. Gene Expression Regulation, Neoplastic. Humans. Mice. Mice, Inbred BALB C. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425728.001).
  • [ISSN] 1615-9861
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Proteins; 0 / RNA, Messenger
  •  go-up   go-down


84. Yang B, Gao YT, Du Z, Zhao L, Song WQ: Methylation-based molecular margin analysis in hepatocellular carcinoma. Biochem Biophys Res Commun; 2005 Dec 23;338(3):1353-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation-based molecular margin analysis in hepatocellular carcinoma.
  • The positive surgical margins are associated with postsurgical recurrence in hepatocellular carcinoma patients, and molecular margin analysis is considered more sensitive in detecting preneoplastic lesions than conventional histological margin examination.
  • The results showed that a considerable frequency (35%, 7 of 20) of CDKN2A methylation was present in histologically negative margins, and methylation pattern analysis might be valuable for studying the cellular origin of recurrent carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cyclin-Dependent Kinase Inhibitor p16 / metabolism
  • [MeSH-minor] Adult. Aged. Base Sequence. Female. Humans. Male. Methylation. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269133.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


85. Wang B, Lu Y, Zhang XF, Yú L, Pan CE, Wu Z: Management of spontaneous rupture of hepatocellular carcinoma. ANZ J Surg; 2008 Jun;78(6):501-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of spontaneous rupture of hepatocellular carcinoma.
  • BACKGROUND: Management of patients with spontaneous rupture of hepatocellular carcinoma in a single centre is reported and the diagnosis and treatment are discussed.
  • METHODS: The clinical presentations, diagnosis and treatment of 28 cases of spontaneous rupture of hepatocellular carcinoma were reviewed.
  • Careful evaluations, including functional liver reserve, coagulopathy, tumour size and location should be made before tumour resection.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / diagnosis. Liver Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease Progression. Embolization, Therapeutic. Female. Hepatectomy. Humans. Male. Middle Aged. Rupture, Spontaneous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18522574.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


86. Matsuno N, Iwamoto H, Nakamura Y, Hama K, Kihara Y, Konno O, Jojima Y, Akashi I, Mijiti A, Ashizawa T, Nagao T: ABO-incompatible adult living donor liver transplantation for hepatocellular carcinoma. Transplant Proc; 2008 Oct;40(8):2497-500
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABO-incompatible adult living donor liver transplantation for hepatocellular carcinoma.
  • Living donor liver transplantation (LDLT) offers timely transplantation for patients with hepatocellular carcinoma (HCC).
  • In this article, we have described 8 adult HCC patients who successfully underwent LDLT from ABO-incompatible donors.
  • Our experience has shown that it is possible to control antibody-mediated humoral rejection and other complications in adult ABO-incompatible LDLT.
  • [MeSH-major] ABO Blood-Group System. Blood Group Incompatibility. Carcinoma, Hepatocellular / surgery. Immunosuppressive Agents / therapeutic use. Liver Neoplasms / surgery. Liver Transplantation / immunology. Living Donors
  • [MeSH-minor] Adult. Drug Therapy, Combination. Graft Rejection / prevention & control. Hepatitis B / surgery. Hepatitis C / surgery. Humans. Immunoglobulin G / blood. Immunoglobulin M / blood. Middle Aged. Neoplasm Staging. Plasmapheresis. Splenectomy. Survival Analysis. Survivors. Treatment Outcome


87. Nalesnik MA, Federle M, Buck D, Fontes P, Carr BI: Hepatobiliary effects of 90yttrium microsphere therapy for unresectable hepatocellular carcinoma. Hum Pathol; 2009 Jan;40(1):125-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatobiliary effects of 90yttrium microsphere therapy for unresectable hepatocellular carcinoma.
  • (90)Yttrium (Therasphere) microspheres administered via hepatic artery are a valuable option for treatment of hepatocellular carcinoma.
  • This retrospective study examines liver explants from 13 adult patients with hepatocellular carcinoma who received intrahepatic Theraspheres and subsequently underwent liver transplantation.
  • No consistent pattern of thrombomodulin loss was seen in endothelial cells of the tumors or adjacent parenchyma, suggesting that direct endothelial cell injury was likely not a major contributor to the necrotic process.
  • However, the pattern of injury and repair is suggestive of a localized and subclinical form of radiation-induced liver disease.
  • [MeSH-major] Brachytherapy / methods. Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy. Microspheres. Yttrium Radioisotopes / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799190.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  •  go-up   go-down


88. Kannangai R, Sahin F, Torbenson MS: EGFR is phosphorylated at Ty845 in hepatocellular carcinoma. Mod Pathol; 2006 Nov;19(11):1456-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR is phosphorylated at Ty845 in hepatocellular carcinoma.
  • Epidermal growth factor receptor (EGFR) is overexpressed in a significant proportion of hepatocellular carcinomas.
  • Recent studies of EGFR inhibitors to treat hepatocellular carcinoma have been encouraging and better understanding of EGFR signaling may lead to more effective strategies for inhibiting this key pathway.
  • Cell line and animal studies have shown that MAPK and STAT-3 are important mediators of the EGFR signal in liver cells.
  • However, little is known about EGFR phosphorylation and subsequent signaling in primary hepatocellular carcinoma.
  • We investigated the site of EGFR phosphorylation by Western blot in 18 hepatocellular carcinomas.
  • Fourteen of 18 hepatocellular carcinomas had detectable EGFR by Western blotting and 13 of 14 showed phosphorylation at tyrosine 845.
  • These findings were further explored by examination of EGFR expression and signaling pathway activation in tissue arrays comprised of 73 hepatocellular carcinomas using antibodies that recognize phosphorylated (or activated) proteins.
  • We conclude that EGFR is phosphorylated at tyrosine 845 in most hepatocellular carcinomas and that EGFR expression by immunohistochemistry does not correlate well with STAT-3, STAT-5, MAPK, or AKT immunostaining.
  • [MeSH-major] Carcinoma, Hepatocellular / chemistry. Liver Neoplasms / chemistry. Receptor, Epidermal Growth Factor / analysis. Tyrosine / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Cell Proliferation. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mitogen-Activated Protein Kinase 1 / analysis. Mitogen-Activated Protein Kinase 3 / analysis. Phosphorylation. Proto-Oncogene Proteins c-akt / analysis. STAT3 Transcription Factor / analysis. STAT5 Transcription Factor / analysis. Signal Transduction. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16936701.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / STAT5 Transcription Factor; 42HK56048U / Tyrosine; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


89. Gorayski P, Thompson CH, Subhash HS, Thomas AC: Hepatocellular carcinoma associated with recreational anabolic steroid use. Br J Sports Med; 2008 Jan;42(1):74-5; discussion 75
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma associated with recreational anabolic steroid use.
  • A 35-year-old male bodybuilder was found to have a hepatocellular carcinoma (HCC) arising in a pre-existing hepatic adenoma following recreational anabolic steroid use.
  • [MeSH-major] Anabolic Agents / adverse effects. Carcinoma, Hepatocellular / chemically induced. Liver Neoplasms / chemically induced. Weight Lifting
  • [MeSH-minor] Adenoma / pathology. Adult. Cell Transformation, Neoplastic / drug effects. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Anabolic Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Sports Med. 2009 Oct 1;43(10):764
  • [ErratumIn] Br J Sports Med. 2010 Oct;44(13):e5
  • (PMID = 18178686.001).
  • [ISSN] 1473-0480
  • [Journal-full-title] British journal of sports medicine
  • [ISO-abbreviation] Br J Sports Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anabolic Agents
  •  go-up   go-down


90. Chan WS, Poon WL, Cho DH, Chiu SS, Luk SH: Transcatheter embolisation of intrahepatic arteriovenous shunts in patients with hepatocellular carcinoma. Hong Kong Med J; 2010 Feb;16(1):48-55
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcatheter embolisation of intrahepatic arteriovenous shunts in patients with hepatocellular carcinoma.
  • This paper assesses the feasibility of transcatheter embolisation of arteriovenous shunts in patients with hepatocellular carcinoma, and reviews available embolic agents, based on our experience and a literature review.
  • From 2001 to 2007, 11 patients with unresectable hepatocellular carcinoma and significant arteriovenous shunts underwent transcatheter embolisation of liver arteriovenous shunts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20124574.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


91. Wei YF, Wang HC, Chang YC: Hemothorax due to metastatic hepatocellular carcinoma presenting with massive hemoptysis. J Formos Med Assoc; 2006 Apr;105(4):346-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemothorax due to metastatic hepatocellular carcinoma presenting with massive hemoptysis.
  • Hemoperitoneum caused by ruptured hepatocellular carcinoma (HCC) is not uncommon in patients with HCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618616.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


92. Hoque HW, Alam S, Ahsan S, Islam MN: Ultrasonography and computer tomography evaluation of hepatocellular carcinoma with cytohistopathological correlation. Bangladesh Med Res Counc Bull; 2007 Aug;33(2):73-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasonography and computer tomography evaluation of hepatocellular carcinoma with cytohistopathological correlation.
  • The prevalence of hepatocellular carcinoma (HCC) in Bangladesh is 35% among all liver diseases.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18481443.001).
  • [ISSN] 0377-9238
  • [Journal-full-title] Bangladesh Medical Research Council bulletin
  • [ISO-abbreviation] Bangladesh Med Res Counc Bull
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Bangladesh
  •  go-up   go-down


93. Kim HC, Chung JW, Jae HJ, Lee W, So YH, Park JH: Hepatocellular carcinoma: transcatheter arterial chemoembolization of the gonadal artery. J Vasc Interv Radiol; 2006 Apr;17(4):703-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma: transcatheter arterial chemoembolization of the gonadal artery.
  • Over the past 9 years, the authors have identified gonadal arteries supplying hepatocellular carcinoma in seven of 4,438 patients (0.16%) whom they attempted to treat by transcatheter arterial chemoembolization.
  • All seven patients had tumors in the Couinaud segment 6 (S6) of the liver (mean size, 6.8 cm).
  • The gonadal artery with anatomic variation may supply hepatocellular carcinomas located in liver S6.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / methods. Gonads / blood supply. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Angiography, Digital Subtraction. Doxorubicin / administration & dosage. Female. Humans. Iodized Oil / administration & dosage. Male. Middle Aged. Radiography, Interventional. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614154.001).
  • [ISSN] 1051-0443
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8001-40-9 / Iodized Oil; 80168379AG / Doxorubicin
  •  go-up   go-down


94. Chen F, Sato K, Fujinaga T, Sonobe M, Shoji T, Sakai H, Miyahara R, Bando T, Okubo K, Hirata T, Date H: Pulmonary resection for metastases from hepatocellular carcinoma. World J Surg; 2008 Oct;32(10):2213-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary resection for metastases from hepatocellular carcinoma.
  • BACKGROUND: Pulmonary metastasectomy has become the standard therapy for various metastatic malignancies to the lungs; however, few data have been available about lung metastasectomy for hepatocellular carcinoma.
  • METHODS: Between 1993 and 2005, 12 patients with pulmonary metastases from hepatocellular carcinomas underwent complete pulmonary resection.
  • All patients had undergone curative resection of their primary hepatocellular carcinomas and also had obtained or had obtainable locoregional control of their primaries.
  • Five patients presented recurrences in the remaining liver before pulmonary metastases, but hepatic recurrences at this interval did not affect an overall survival after pulmonary metastasectomies.
  • Two patients had undergone living-related liver transplantation.
  • CONCLUSIONS: Pulmonary metastasectomy for hepatocellular carcinoma in selected patients was well justified when the maximum tumor size was <3 cm.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Longitudinal Studies. Male. Middle Aged. Neoplasm Recurrence, Local / therapy. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18668285.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Hol L, van den Bos IC, Hussain SM, Zondervan PE, de Man RA: Hepatocellular carcinoma complicating biliary atresia after Kasai portoenterostomy. Eur J Gastroenterol Hepatol; 2008 Mar;20(3):227-31
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma complicating biliary atresia after Kasai portoenterostomy.
  • Kasai portoenterostomy (PE) increases the survival for children with biliary atresia (BA) and consequently postpones subsequential liver transplantation.
  • We report a case of hepatocellular carcinoma (HCC) in a 19-year-old male patient with BA and Kasai PE.
  • Pathologic findings of the mass, after orthotopic liver transplantation, demonstrated a well-differentiated HCC (T1N0M0).
  • Repeated sequential magnetic resonance imaging of the native liver in patients with Kasai PE is necessary to monitor possible malignant transformation of liver nodules that may potentially develop as a result of chronic cholestatic liver disease.
  • [MeSH-major] Biliary Atresia / surgery. Carcinoma, Hepatocellular / etiology. Liver Neoplasms / etiology. Portoenterostomy, Hepatic / adverse effects
  • [MeSH-minor] Humans. Magnetic Resonance Imaging. Male. Young Adult

  • Genetic Alliance. consumer health - Biliary Atresia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301305.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


96. Gotohda N, Ishii H, Konishi M, Nakagohri T, Takahashi S, Furuse J, Yoshino M, Kinoshita T: Selection criteria for reduction hepatectomy in multiple advanced hepatocellular carcinoma. Anticancer Res; 2006 Nov-Dec;26(6C):4671-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selection criteria for reduction hepatectomy in multiple advanced hepatocellular carcinoma.
  • BACKGROUND: Few studies have compared the prognostic impact of reduction hepatectomy (RH) for advanced hepatocellular carcinoma (HCC) with that of non-surgical treatment or curative hepatectomy.
  • RESULTS: In patients with tumor extension in >50% of the liver, 1-year survival rates for patients according to treatment (RH, control A and B) were 50%, 90% and 11% and 3-year survival rates were 42%, 60% and 0%, respectively.
  • CONCLUSION: RH could be recommended to patients with multiple advanced HCC extending to >50% of the whole liver.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatectomy. Humans. Male. Middle Aged. Patient Selection. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214325.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


97. Lin CH, Chang WN, Lu CH, Tsai NW, Lui CC, Chuang YC, Huang CR, Chen SF, Chang CC, Wang HC, Yang TM, Hsieh MJ: Clinical characteristics of spinal involvement in hepatocellular carcinoma. Acta Neurol Taiwan; 2009 Dec;18(4):255-61
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of spinal involvement in hepatocellular carcinoma.
  • PURPOSE: To analyze the clinical characteristics of hepatocellular carcinoma (HCC) with spinal metastasis.
  • Viral hepatitis and liver cirrhosis are common preceding events in patients with HCC with spinal involvement.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Spinal Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Female. Glasgow Coma Scale. Hepatitis, Viral, Human / complications. Humans. Liver Cirrhosis / complications. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20329593.001).
  • [ISSN] 1028-768X
  • [Journal-full-title] Acta neurologica Taiwanica
  • [ISO-abbreviation] Acta Neurol Taiwan
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


98. El-Kafrawy SA, Abdel-Hamid M, El-Daly M, Nada O, Ismail A, Ezzat S, Abdel-Latif S, Abdel-Hamid A, Shields PG, Loffredo C: P53 mutations in hepatocellular carcinoma patients in Egypt. Int J Hyg Environ Health; 2005;208(4):263-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P53 mutations in hepatocellular carcinoma patients in Egypt.
  • The p53 gene plays a major role in hepatocellular carcinoma (HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Genes, p53 / genetics. Hepacivirus / genetics. Liver Neoplasms / genetics. Mutation
  • [MeSH-minor] Adult. Aged. DNA Mutational Analysis. Egypt. Exons. Female. Hepatitis C / complications. Hepatitis C / genetics. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. RNA, Viral / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16078640.001).
  • [ISSN] 1438-4639
  • [Journal-full-title] International journal of hygiene and environmental health
  • [ISO-abbreviation] Int J Hyg Environ Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


99. Lou C, Yang B, Gao YT, Wang YJ, Nie FH, Yuan Q, Zhang CL, Du Z: [Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi; 2008 Nov;30(11):831-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma].
  • OBJECTIVE: To investigate the methylation frequencies of multiple tumor suppressor genes (TSGs) in hepatocellular carcinoma (HCC) and the clinical implication of aberrant DNA methylation in molecular carcinogenesis of HCC.
  • METHODS: Sixty samples of HCC and the paired adjacent liver tissue, 16 samples from post-hepatitis cirrhotic livers, 5 from livers with chronic hepatitis and 5 from normal livers were collected.
  • The methylation rate of MGMT, GSTP1 and RIZ1 in the adjacent tissues was 41.6%, 40.0% and 25.0%, respectively, significantly higher than that in cirrhotic liver (P < 0.05).
  • CONCLUSION: Different frequency of methylation in hepatocellular carcinomas, adjacent liver tissues and cirrhotic livers implies that epigenetic alteration in the hepatocellular carcinogenesis may be a gradually progressive process.
  • Methylation status of MGMT, GSTP1 and RIZ1 may be promising in risk assessment of hepatocellular carcinoma and in early diagnosis.
  • Furthermore, MGMT methylation might be also used as a potential prognostic biomarker for hepatocellular carcinoma patients.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. DNA Methylation. Genes, Tumor Suppressor. Liver Neoplasms / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Base Sequence. DNA Modification Methylases / genetics. DNA Modification Methylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. DNA, Neoplasm / genetics. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Disease-Free Survival. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Glutathione S-Transferase pi / genetics. Glutathione S-Transferase pi / metabolism. Hepatitis B, Chronic / genetics. Hepatitis B, Chronic / metabolism. Histone-Lysine N-Methyltransferase. Humans. Liver / metabolism. Liver Cirrhosis / genetics. Liver Cirrhosis / metabolism. Male. Middle Aged. Molecular Sequence Data. Neoplasm Recurrence, Local. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. Transcription Factors / genetics. Transcription Factors / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173828.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / RASSF1 protein, human; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.1.1.43 / PRDM2 protein, human; EC 2.1.1.63 / MGMT protein, human; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


100. Kang YK, Hong SW, Lee H, Kim WH: Prognostic implications of ezrin expression in human hepatocellular carcinoma. Mol Carcinog; 2010 Sep;49(9):798-804
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of ezrin expression in human hepatocellular carcinoma.
  • The authors investigated ezrin expression in human hepatocellular carcinoma (HCC) and sought to determine its relation with clinicopathologic parameters, patients' outcome, and interacting molecular markers.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / metabolism. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers / metabolism. Cadherins. Cytoskeletal Proteins. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasms / pathology. Prognosis. Young Adult






Advertisement